TWI572345B - An absorbent article, a topsheet of an absorbent article, and a method for producing the same - Google Patents

Description

Absorbent article, surface layer sheet of absorbent article, and method for producing the same

The present invention relates to an absorbent article such as a disposable diaper or a sanitary napkin, a surface sheet of an absorbent article, and a method for producing the surface sheet.

It is known that the film layer which is in contact with the skin and the two layers of the fiber layer facing the absorber side are integrated into a surface material, and the film layer is made of an opaque hydrophobic resin having a top portion, a bottom portion and a wall portion connecting the same. The surface material of the sanitary article having at least one of the wall portions and having no opening at the bottom is a prior art (for example, Patent Document 1). The surface material is excellent in liquid permeability, backflow prevention property, shielding property, and hanging property.

Advanced technical literature Patent literature

Patent Document 1 Japanese Patent Laid-Open No. 1-119251

However, in the past surface material described in Patent Document 1, when the surface material is used as a surface sheet of a disposable diaper or a sanitary napkin, a portion of the body fluid that has moved to the absorber through the opening of the surface material remains. In the fiber layer. At this time, if pressure is applied to the surface material, the body fluid remaining in the fiber layer passes through the opening of the surface material and moves to the skin of the user, so that the user has a species The feeling of stickiness.

The present invention has an object of providing a method for producing an absorbent article capable of suppressing residual body fluid of a fiber layer of a surface sheet, a surface sheet of the absorbent article, and a surface sheet thereof.

In order to solve the above problems, the present invention adopts the following configuration.

In other words, the present invention is a surface layer sheet provided with a liquid permeability on the skin side, a liquid-impermeable back sheet provided on the garment side, and a liquid-retaining absorber provided between the surface sheet and the back sheet. In the absorbent article, the surface sheet is a resin-containing layer provided on the garment side of the resin film layer, and a blood modifying agent layer provided on the skin side of the resin film layer, and the surface layer sheet is juxtaposed. a plurality of ridge portions disposed below and a bottom portion disposed between the adjacent ridge portions, and the ridge portion is a wall portion having a plurality of openings in the direction in which the ridge portions extend in the direction in which the ridge portions extend, and the fiber gathers The fiber of the layer is covered with a blood modifying agent of the blood modifying agent layer, and the blood modifying agent has an IOB of 0 to 0.60, a melting point of 45 ° C or less, and a water solubility of 0.05 g or less of 100 g of water at 25 ° C.

Further, the present invention is a liquid permeable surface layer sheet for use in an absorbent article, wherein the surface layer sheet is a resin layer layer including a resin film layer provided on one surface of the resin film layer, and is provided on the other surface of the resin film layer. In the blood modifying agent layer, the surface layer sheet has a plurality of ridge portions arranged in parallel and a bottom portion disposed between the adjacent ridge portions, and the ridge portion has a parallel direction in which the resin film layer extends in the direction in which the ridge portions extend. The wall of the opening contains On the side surface, the fibers of the fiber assembly layer are covered by a blood modifying agent of the blood modifying agent layer, and the blood modifying agent is a plasma modifying agent having an IOB of 0 to 0.60 and a melting point of 45 ° C or less. Water solubility of 0.05 g or less of 100 g of water at 25 ° C.

Further, the present invention relates to a method for producing a surface sheet for an absorbent article, comprising the steps of: preparing a composite sheet containing a fiber assembly layer and a resin film layer; and stretching the composite sheet through a gear to form a plurality of protrusions arranged in parallel a step of forming a portion of the composite sheet, a step of applying a blood modifying agent on the surface of the resin film layer of the composite sheet forming the ridge portion, and a step of forming the ridge portion in the step of forming the composite sheet, The plurality of openings that are juxtaposed in the direction in which the ridges are extended are included in the wall portion of the resin film layer, and the fibers of the fiber collection layer are covered with a blood modifying agent, and the blood modifying agent has an IOB of 0 to 0.60, 45 ° C. The following melting point and water solubility of 0.05 g or less of 100 g of water at 25 °C.

In the present invention, the body fluid remaining in the fiber assembly layer of the surface layer sheet can be suppressed.

Form of implementing the invention

The invention will be described below with reference to the drawings, but the invention is not limited by the drawings.

1 is a partially broken plan view of an absorbent article according to an embodiment of the present invention, and FIG. 2 is a schematic cross-sectional view of the A-A broken surface shown in FIG. 1, FIG. It is a mode oblique view of the surface sheet 2. The absorbent article 1 is provided with a liquid permeable surface layer 2 provided on the skin side, a liquid impervious back sheet 3 provided on the garment side, and a liquid retaining property provided between the surface sheet 2 and the back sheet 3. The absorber 4 is. The back sheet 3 is formed to extend in the width direction to form a pair of wing portions 5. An adhesive portion 6 is provided on the garment side of the wing portion 5. In addition, in FIG. 1, the width direction of the absorbent article 1 is the X-axis direction, and the longitudinal direction is the Y-axis direction. Further, the plane direction of the absorbent article 1 is the XY direction.

The top sheet 2 is a moving body fluid such as urine or menstrual blood discharged from the user to the absorbent body 4. At least a portion of the surface sheet 2 is liquid permeable. Further, the surface sheet 2 is intended to reduce the contact area between the skin of the user and the surface sheet 2, and the skin contact of the top sheet 2 is good, and the cross section in the width direction is curved in a slightly wavy shape. Further, the surface sheet 2 has a section in the longitudinal direction which can be bent into a slightly wavy shape.

The surface sheet 2 in which the cross section in the width direction is curved in a slightly wavy shape has a bottom portion 22 disposed between the ridge portion 21 extending in the longitudinal direction and the adjacent ridge portion 21. Further, the extending direction of the ridge portion 21 is not limited to the long direction. The ridge portion 21 is a wall portion 24 having a top portion 23 and a side surface of the surface in contact with the skin of the user.

The top sheet 2 is a resin film layer 31 including a plurality of openings 34 to be permeated through the body fluid, a blood modifying agent layer 33 provided on the skin side of the resin film layer 31, and a coating side provided on the resin film layer 31. Fiber collection layer 32. The fiber assembly layer 32 is caused by destruction of the substrate to the wall portion 24 of the ridge portion 21. Among them, the substrate is broken into a broken toilet paper layer, etc. Destruction of the tissue layer produced inside the tissue layer.

The resin used as the resin film layer 31 is a copolymer of an olefin with another monomer such as acrylate or vinyl acetate, polyolefin, polyester, polypropylene, polyethylene, polyethylene terephthalate, polyamine, Or cellulose acetate and the like. From the viewpoint of high flexibility and less irritation to the skin, the resin film used for the resin film layer 31 is preferably polyethylene, and more preferably low-density polyethylene.

The basis weight of the resin film layer 31 is preferably 1 g/m ² or more, more preferably 30 g/m ² or less, and more preferably 3 g/m ² or more and 15 g/m ² or less. Further, the thickness of the resin film layer 31 is preferably 0.01 mm or more and 0.3 mm or less, more preferably 0.03 mm or more, and still more preferably 0.15 mm or less. When the thickness of the resin film layer 31 is less than 0.01 mm, the concealability of the surface sheet 2 to be described later may be too small. When the thickness of the resin film layer 31 exceeds 0.3 mm, the rigidity of the surface sheet 2 may become high or may be used. The irritation of the topsheet 2 of the skin of the person is too strong. When the thickness of the resin film layer 31 exceeds 0.3 mm, the strength of the resin film layer 31 is excessively high, and the opening portion 34 is not formed on the resin film layer 31.

The topsheet 2 is intended to make the body fluid absorbed in the absorbent body 4 invisible from the outside. The concealability of the surface sheet 2 is caused by the concealability of the resin film layer 31. The concealability of the resin film layer 31 is produced by mixing an inorganic filler such as titanium oxide with a resin. When the filler is titanium oxide, the content of the titanium oxide is preferably 1% or more and 50% or less, more preferably 3% or more and 15% or less, based on the weight of the resin. When the content of the titanium oxide is less than 1% by weight of the resin, the surface layer 2 is in the absorber 4 The concealing effect of the absorbed body fluids is too small. When the content of the titanium oxide exceeds 50% by weight of the resin film, the resin containing titanium oxide may be difficult to form into a layer.

In the wall portion 24 of the surface sheet 2, the resin film layer 31 has a plurality of parallel openings 34 in the direction in which the ridge portions 21 are elongated (long direction). The opening 34 is a hole penetrating the resin film layer 31, and the body fluid of the user is absorbed by the absorber 4 through the opening 34 in the fiber assembly layer 32. The opening area of the opening portion 34 is preferably 0.0005 mm ² or more and 1.5 mm ² or less, and more preferably 0.01 mm ² or more and 0.5 mm ² or less. Area of the opening portion 34 than 0.0005mm ² hours with the body fluids are sometimes does not pass through the opening portion 34, the body fluid absorbed in the area of the opening portion 34 when the ^second large than 1.5mm, the absorbent member 4 will once The area ratio of the portion other than the opening portion 34 of the resin film layer 31 is reduced by the back portion 34 of the resin film layer 31, or the concealability of the surface sheet 2 is reduced. When the opening area of the opening 34 of the resin film layer 31 is larger than 1.5 mm ² , the strength of the surface sheet 2 may be too small.

The ratio of the total opening area of the area of the resin film layer 31, that is, the opening ratio of the resin film layer 31 is preferably 1% or more and 10% or less. When the aperture ratio of the resin film layer 31 is less than 1%, the permeability of the body fluid in the surface layer sheet 2 is deteriorated, and when the aperture ratio of the resin film layer 31 is larger than 10%, the body fluid which is absorbed in the absorber 4 passes. The opening portion 34 of the resin film layer 31 flows back, or the ratio of the area of the portion other than the opening portion 34 of the resin film layer 31 becomes small, or the concealability of the surface sheet 2 becomes small. Further, when the aperture ratio of the resin film layer 31 is larger than 10%, the surface sheet 2 is The intensity will be too small.

The fiber assembly layer 32 is a paper containing a collection of hydrophilic fibers, a nonwoven fabric, or the like. The nonwoven fabric used as the fiber assembly layer 32 is preferably toilet paper. In addition, the toilet paper is a thin leaf paper which has a wet strength of 10 g/m ² or more and 20 g/m ² or less as a main component, such as kraft pulp or crepe. The thickness of the fiber assembly layer 32 is preferably 0.1 mm or more and 0.5 mm or less. The resin film layer 31 can impart hydrophilicity to the surface sheet 2 even if it does not have hydrophilicity. Further, the fiber assembly layer 32 can impart flexibility to the surface sheet 2. When the toilet paper is used for the fiber assembly layer 32, the toilet paper is relatively inexpensive compared to other papers and non-woven fabrics, and can be easily purchased in many cycles on the market. Further, although the strength of the toilet paper is low, when the resin film layer 31 is used at the same time, the toilet paper as the fiber assembly layer 32 of the surface sheet 2 can be used. Further, since the toilet paper is easily broken by the base material, the opening portion 34 can be easily formed in the resin film layer 31 by the gear extending step described later.

The blood modifying agent layer 33 is a body fluid for suppressing the user, and particularly a body fluid having a high viscosity remains on the surface of the surface sheet 2. The fibers of the fiber assembly layer 32 are covered with the blood modifying agent of the blood modifying agent layer 33, and the body fluid that has entered from the opening 34 does not remain in the fiber assembly layer 32 and is absorbed by the absorber. Thereby, the body fluid of the user can be suppressed, and in particular, the body fluid having a high viscosity remains in the fiber assembly layer 32. Therefore, when the pressure is applied to the surface sheet 2, the body fluid remaining in the fiber assembly layer 32 can be prevented from passing through the opening portion 34 of the surface sheet 2 and moved to the skin of the user. Thereby, when the pressure is applied to the surface sheet 2, the body fluid remaining in the fiber collection layer 32 can be prevented from passing through the surface sheet 2 The opening portion 34 is placed on the user's skin to give a sticky feeling to the user.

A blood modifying agent is applied to the surface of the surface sheet 2 to form a blood modifying agent layer 27 on the skin side surface of the top sheet 2. By the blood modifying agent layer 33, on the surface of the surface sheet 2, the body fluid of the user can be suppressed, and in particular, the menstrual blood having high viscosity can be left. The blood modifying agent of the blood modifying agent layer 33 is a blood modifying agent of the present invention, which has an IOB of about 0 to about 0.60, a melting point of about 45 ° C or less, and a water solubility of about 0.05 g or less at 25 ° C. .

IOB (Inorganic Organic Balance) indicates the balance index of hydrophilicity and lipophilicity. In this specification, it is the formula of Oda: IOB=inorganic value/organic value

The calculated value.

The inorganic value and the organic value are based on the organic concept map described in the area Vol. 11, No. 10 (1957) p. 719-725, which is based on Fujita Mu's "Predicting and Organic Concepts of Organic Compounds".

The organic and inorganic values of the main base are summarized by Fujita as Table 1 below.

For example, an ester of a carbon number of 14 tetradecanoic acid and a carbon number 12 dodecyl alcohol has an organic value of 520 (CH ₂ , 20 × 26) and an inorganic value of 60 (-COOR, 60 × 1), so IOB = 0.12.

For the above blood modifying agent, IOB is preferably from about 0 to about 0.60, preferably from about 0 to about 0.50, more preferably from about 0 to about 0.40, most preferably from about 0 to about 0.30. Because the lower the IOB, the higher the organicity, the higher the affinity with the blood cells.

The "melting point" in this specification is measured by a differential scanning calorimeter. The temperature at the temperature increase rate of 10 ° C / min was changed from the solid state to the peak temperature of the endothermic peak at the time of liquid. The melting point is measured by, for example, a DSC-60 type DSC measuring apparatus manufactured by Shimadzu Corporation, at a temperature increase rate of 10 ° C / min.

The blood modifying agent may have a melting point of about 45 ° C or less, may be liquid at room temperature, or may be solid, that is, the melting point may be above about 25 ° C, or may be less than about 25 ° C, for example, may have about -5 °C, about -20 ° C and other melting points. The melting point of the above blood modifying agent may be about 45 ° C or less as shown below.

The blood modifying agent has no lower limit at the melting point, but the vapor pressure is preferably lower. The vapor pressure of the blood modifying agent is preferably about 0.01 Pa or less at 1 atm and 25 ° C, preferably about 0.001 Pa or less, more preferably about 0.0001 Pa or less. The absorbent article disclosed in the present invention is preferably used in contact with a human body, and the vapor pressure is preferably about 0.01 Pa or less at 1 atm and 40 ° C, preferably about 0.001 Pa or less, and about 0.0001 Pa or less. For better. Because if the vapor pressure is high, there will be problems such as gasification during storage, reduction of blood reforming dose, and odor during use.

Moreover, the melting point of the blood modifying agent can be classified according to the climate, the length of time of use, and the like. For example, when a blood modifying agent having a melting point of about 10 ° C or less is used in an area having an average temperature of 10 ° C or less, it can be cooled by ambient temperature after excretion by blood, and the blood modifying agent can stably reform the blood.

Further, when the absorbent article is used for a long period of time, the melting point of the blood modifying agent is preferably higher in the range of 45 ° C or lower. Because it is not easily affected by sweat, friction during use, etc., it is not easy to move the blood modifying agent even if it is used for a long time.

When the water solubility is 25 ° C, 0.05 g of the sample is added to 100 g of the deionized water, and allowed to stand for 24 hours. After 24 hours, it is simply stirred as necessary, and it is judged whether or not the sample has a water solubility of 0.05 g or less or not.

Further, in the present specification, in the "dissolution" of the water solubility, the sample is completely dissolved in the deionized water, and the case where the homogeneous mixture is formed and the sample is completely emulsified is included. Further, the term "complete" means a block shape in which no sample is present in the deionized water.

In this technical field, the surface tension of blood is changed, and the blood is rapidly absorbed for the purpose, and the surface of the surface sheet is coated with a surfactant. However, since the surfactant has a high water solubility in general, the surface layer coated with the surfactant is easily mixed with a hydrophilic component (plasma, etc.) in the blood, in other words, has a function of retaining blood in the surface sheet. Propensity. Since the above-mentioned blood modifying agent has a low water solubility, it is different from the conventionally known surfactant, and the blood does not remain in the surface layer sheet, and can be quickly moved to the absorber.

In the present specification, the solubility in 100 g of water at 25 ° C is sometimes referred to only as "water solubility".

The above blood modifying agent may have a water solubility of about 0 g. Therefore, for the above blood modifying agent, the lower limit of the water solubility is about 0 g.

Examples of the blood modifying agent include compounds having the following structures.

(i) a hydrocarbon, (ii) between the C-C single bonds of the hydrocarbon, inserted with at least one carbonyl bond (-CO- And/or at least one compound of an ether bond (-O-), or (iii) intercalated with at least one carbonyl bond (-CO-) and/or at least one ether bond between the CC single bonds of the hydrocarbon (- O-), and a compound in which at least one hydrogen atom on a hydrocarbon is substituted by a carboxyl group (-COOH) or a hydroxyl group (-OH).

In the present specification, the term "hydrocarbon" means a compound derived from carbon and hydrogen, and the chain hydrocarbon is, for example, selected from a paraffinic hydrocarbon (which does not contain a double bond or a hydrazine, also referred to as an alkane) or an olefinic hydrocarbon (containing one). Double bond, also known as olefin), acetylene hydrocarbon (containing one bond, also known as alkyne), and two or more bonded hydrocarbons selected from the group consisting of a double bond and a bond, and a cyclic hydrocarbon For example, an aromatic hydrocarbon or an alicyclic hydrocarbon can be mentioned.

As the hydrocarbon, a chain hydrocarbon or an alicyclic hydrocarbon is preferred, and a chain hydrocarbon is preferred, and a paraffinic hydrocarbon, an olefin hydrocarbon, and a hydrocarbon having two or more double bonds (having no reference) are used. More preferred, and paraffinic hydrocarbons are preferred.

The chain hydrocarbons contain a linear hydrocarbon and a branched hydrocarbon.

When two or more ether bonds (-O-) are inserted into the compounds of the above (ii) and (iii), the ether bonds (-O-) are not adjacent to each other. Therefore, the compounds of the above (ii) and (iii) do not contain a compound having a continuous ether bond (so-called peroxide).

Further, in the compound of the above (iii), a compound in which at least one hydrogen atom on a hydrocarbon is substituted by a carboxyl group (-COOH), and a compound in which at least one hydrogen atom on a hydrocarbon is substituted with a hydroxyl group (-OH) is preferred. . As shown in Table 1, the carboxyl group is combined with the metal in the menstrual blood, and the inorganic value 150 is greatly increased to 400 or more. Therefore, the blood modifying agent having a carboxyl group rises to an IOB value of about 0.6 at the time of use, and is compatible with the blood cell. There is a possibility that sex will decrease.

The above blood modifying agent is preferably a compound having the following structure.

(i') a hydrocarbon, (ii') inserted between at least one carbonyl bond (-CO-), at least one ester bond (-COO-), and at least one carbonate bond (-OCOO) between hydrocarbon single bonds of hydrocarbons -) and / or at least one ether bond (-O-) compound, or (iii') between the hydrocarbon CC single bond, inserted at least one carbonyl bond (-CO-), at least one ester bond (- COO-), at least one carbonate bond (-OCOO-) and/or at least one ether bond (-O-), and at least one hydrogen atom on the hydrocarbon is derived from a carboxyl group (-COOH) or a hydroxyl group (-OH) Substituted compound.

For the compounds of the above (ii') and (iii'), when two or more bonds are inserted, the insertion is selected from a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonate bond (-OCOO). -) When two or more bonds of the ether bond (-O-) are bonded, the bonds are not adjacent to each other, and at least one carbon atom is interposed between the bonds.

More preferably, the above-mentioned blood modifying agent has a carbonyl bond (-CO-) of about 1.8 or less per 10 carbon atoms, an ester bond (-COO-) of 2 or less, and a carbonate bond (-OCOO-) of about 1.5. The following are compounds having an ether bond (-O-) of about 6 or less, a carboxyl group (-COOH) of about 0.8 or less, or a hydroxyl group (-OH) of about 1.2 or less.

More preferably, the blood modifying agent is (A) an ester of a compound having 2 to 4 hydroxyl groups and a compound having one carboxyl group, (B) an ether having a compound having 2 to 4 hydroxyl groups and an ether having a hydroxyl group, (C) an ester of a compound having 2 to 4 carboxyl groups and a compound having 1 hydroxyl group, and (D) a hydrocarbon insertion selected from a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (- a compound of one of OCOO-) and an ether bond (-O-), (E) a poly C ₃ -C ₆ alkanediol, or an alkyl ester or alkyl ether thereof, or (F) a chain hydrocarbon .

The following explains (A) to (F) in detail.

[(A) an ester of a compound having 2 to 4 hydroxyl groups and a compound having 1 carboxyl group]

(A) an ester having a compound having 2 to 4 hydroxyl groups and an ester having a compound having one carboxyl group (hereinafter sometimes referred to as "compound (A)"), and a compound having 4, 3 or 2 hydroxyl groups and An ester having a compound having one carboxyl group, the above IOB is only in a range having a melting point and a water solubility, and all of the hydroxyl groups need not be esterified.

As the compound having the above 2 to 4 hydroxyl groups, for example, a chain hydrocarbon tetraol, such as an alkanetetraol, such as pentaerythritol, a chain hydrocarbon triol, such as an alkane triol such as glycerin, and a chain hydrocarbon diol such as an alkane Alcohols such as glycols are exemplified. As the compound having the above one carboxyl group, for example, a compound in which one hydrogen atom on a hydrocarbon is substituted by one carboxyl group (-COOH), for example, a fatty acid may be mentioned.

Examples of the compound (A) include an ester of (A ₁ ) chain hydrocarbon tetraol and a fatty acid, an ester of (A ₂ ) chain hydrocarbon triol and a fatty acid, and (A ₃ ) a chain hydrocarbon diol and a fatty acid. Ester.

[(A ₁ ) ester of chain hydrocarbon tetraol with fatty acid]

As the ester of the above chain hydrocarbon tetraol and a fatty acid, for example, the following formula (1):

Pentaerythritol and a tetraester of a fatty acid, the following formula (2):

a pentaerythritol and a fatty acid triester, the following formula (3):

a diester of pentaerythritol and a fatty acid, the following formula (4):

The monoester of pentaerythritol and a fatty acid can be mentioned.

(wherein, R ¹ to R ^{4 are} each a chain hydrocarbon)

As the fatty acid (R ¹ COOH, R ² COOH, R ³ COOH, and R ⁴ COOH) constituting the ester of the pentaerythritol and the fatty acid, the ester of pentaerythritol and a fatty acid may be a component satisfying the above IOB, melting point, and water solubility, and There is no particular limitation, such as a saturated fatty acid such as a C ₂ - C ₃₀ saturated fatty acid such as acetic acid (C ₂ ) (C ₂ represents a carbon number, which is equivalent to a carbon of R ¹ C, R ² C, R ³ C or R ⁴ C Number, the same below), propane acid (C ₃ ), butanoic acid (C ₄ ) and isomers thereof, such as 2-methylpropanic acid (C ₄ ), pentanoic acid (C ₅ ) and isomers thereof For example, 2-methylbutanoic acid (C ₅ ), 2,2-dimethylpropane acid (C ₅ ), hexane acid (C ₆ ), heptanoic acid (C ₇ ), octanoic acid (C ₈ And its isomers, such as 2-ethylhexane acid (C ₈ ), decanoic acid (C ₉ ), decanoic acid (C ₁₀ ), dodecanoic acid (C ₁₂ ), tetradecanoic acid ( C ₁₄ ), palmitic acid (C ₁₆ ), heptadecanoic acid (C ₁₇ ), octadecanoic acid (C ₁₈ ), icosonic acid (C ₂₀ ), behenic acid (C ₂₂ ), twenty Tetraacid (C ₂₄ ), hexadecanoic acid (C ₂₆ ), octadecanoic acid (C ₂₈ ), tridecanoic acid (C ₃₀ ), and the like, and these isomers (excluding the above) may be mentioned.

The above fatty acid may be an unsaturated fatty acid. As the above unsaturated fatty acid, for example, a C ₃ - C ₂₀ unsaturated fatty acid such as a monounsaturated fatty acid such as crotonic acid (C ₄ ), myristic acid (C ₁₄ ), palmitoleic acid (C ₁₆ ), oleic acid ( C ₁₈ ), oleic acid (C ₁₈ ), octadecenoic acid (C ₁₈ ), oleic acid (C ₂₀ ), eicosaenoic acid (C ₂₀ ), etc., diunsaturated fatty acids, such as linoleic acid (C ₁₈ ), eicosadienoic acid (C ₂₀ ), etc., triunsaturated fatty acids, such as linolenic acid, such as α-linolenic acid (C ₁₈ ) and γ-linolenic acid (C ₁₈ ), pine acid (C) ₁₈ ), tung oil, such as α-tricoleic acid (C ₁₈ ) and β-tricoleic acid (C ₁₈ ), mead (C ₂₀ ), dihomo-γ-linolenic acid (C ₂₀ ), eicosatrienoic acid (C _20), etc., tetrakis unsaturated fatty acids such as stearidonic acid (C _20), arachidonic acid (C _20), arachidonic acid (C _20), etc., five unsaturated fatty acids, e.g. Examples of the eicosatetraenoic acid (C ₁₈ ), eicosapentaenoic acid (C ₂₀ ), and the like, and some of the hydrogen adducts thereof may be mentioned.

As the ester of the pentaerythritol and the fatty acid, it is preferable to use an ester of pentaerythritol and a fatty acid derived from a saturated fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid, in consideration of modification by oxidation or the like.

Further, as the ester of the pentaerythritol and the fatty acid, the IOB is required to be smaller and more hydrophobic, and a diester, a triester or a tetraester is preferred, a triester or a tetraester is preferred, and a tetraester is preferred.

In the tetraester of the pentaerythritol and the fatty acid, the total number of carbon atoms of the fatty acid constituting the tetraester of pentaerythritol and the fatty acid, that is, the carbon number of the R ¹ C, R ² C, R ³ C and R ⁴ C portions of the above formula (1) The total IOB is 0.60 at 15 o'clock. Therefore, in the tetraester of pentaerythritol and fatty acid, when the total number of carbon atoms is about 15 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

Among the above tetraesters of pentaerythritol and fatty acids, for example, pentaerythritol, hexane acid (C ₆ ), heptanoic acid (C ₇ ), octanoic acid (C ₈ ), such as 2-ethylhexane acid (C ₈ ), A tetraester of decanoic acid (C ₉ ), decanoic acid (C ₁₀ ) and/or dodecanoic acid (C ₁₂ ) may be mentioned.

In the above-mentioned pentaerythritol and fatty acid triester, the total number of carbon atoms of the fatty acid constituting the trimer of the pentaerythritol and the fatty acid is 19, when the carbon number of the R ¹ C, R ² C and R ³ C portions is 19 in total. The IOB became 0.58. Therefore, in the above-mentioned pentaerythritol and fatty acid triester, when the total carbon number of the fatty acid is about 19 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

In the diester of the pentaerythritol and the fatty acid, the carbon number of the fatty acid constituting the diester of the pentaerythritol and the fatty acid is a total of, that is, when the carbon number of the R ¹ C and R ² C portions is 22 in the above formula (3), the IOB is 0.59. Therefore, in the diester of the pentaerythritol and the fatty acid, when the total carbon number of the fatty acid is about 22 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

The monoester of the pentaerythritol and the fatty acid constitutes the fatty acid carbon number of the pentaerythritol and the monoester of the fatty acid, that is, for the above formula (4), when the carbon number of the R ¹ C moiety is 25, the IOB is 0.60. Therefore, in the monoester of the pentaerythritol and the fatty acid, when the carbon number of the fatty acid is about 25 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

And for the above calculations, the effects of double bonds, reference keys, iso branches, and tert branches are not considered.

As a commercial product of the above-mentioned ester of pentaerythritol and a fatty acid, Yunisuta H-408BRS, H-2408BRS-22 (mixed product), etc. (The above is manufactured by Nippon Oil Co., Ltd.) can be mentioned.

[(A ₂ ) chain hydrocarbon triol and ester of fatty acid]

As the ester of the above chain hydrocarbon triol and a fatty acid, for example, the following formula (5):

Glycerol and fatty acid triester, the following formula (6):

The diester of glycerol and fatty acid, and the following formula (7):

(wherein R ⁵ to R ^{7 are} each a chain hydrocarbon)

The monoglyceride of glycerin and fatty acid can be mentioned.

The fatty acid (R ⁵ COOH, R ⁶ COOH, and R ⁷ COOH) constituting the ester of the glycerin and the fatty acid, and the ester of the glycerin and the fatty acid are only required to satisfy the requirements of the above IOB, the melting point, and the water solubility, and are not particularly limited. For example, the fatty acids listed in "(A ₁ ) chain hydrocarbon tetraol and fatty acid esters", that is, saturated fatty acids and unsaturated fatty acids, may be exemplified by saturated fatty acids in consideration of the possibility of modification by oxidation or the like. The ester of glycerol and a fatty acid, that is, an ester of glycerin and a saturated fatty acid is preferred.

Further, as the ester of the above glycerin and a fatty acid, the IOB is intended to be small, so that When it is more hydrophobic, a diester or a triester is preferred, and a triester is preferred.

The above triglycerides of glycerol and fatty acid are also known as triglycerides, such as triesters of glycerol and octanoic acid (C ₈ ), triesters of glycerol and decanoic acid (C ₁₀ ), glycerol and dodecanoic acid (C ₁₂ ) Triesters, and glycerides and triesters of two or three kinds of fatty acids, and mixtures thereof may be mentioned.

As the triester of the above glycerin and two or more kinds of fatty acids, for example, a triester of glycerin and octanoic acid (C ₈ ) and decanoic acid (C ₁₀ ), glycerin and octanoic acid (C ₈ ), and decanoic acid (C) ₁₀ ) and tridecanoic acid (C ₁₂ ) triester, glycerol and octanoic acid (C ₈ ), decanoic acid (C ₁₀ ), dodecanoic acid (C ₁₂ ), tetradecanoic acid (C ₁₄ ) Examples of the triester of palmitic acid (C ₁₆ ) and octadecanoic acid (C ₁₈ ) include the following.

The triglyceride of the glycerin and the fatty acid is such that the melting point is about 45° C. or less, and the carbon number of the fatty acid constituting the triester of glycerin and the fatty acid is total, that is, R ⁵ C, R ⁶ C and R ⁷ C in the formula (5). A part of the total carbon number is preferably about 40 or less.

Further, in the triglyceride of the glycerin and the fatty acid, the carbon number of the fatty acid constituting the triester of glycerin and the fatty acid is total, that is, the total number of carbon atoms of the R ⁵ C, R ⁶ C and R ⁷ C portions in the formula (5) is 12 The IOB becomes 0.60. Therefore, in the above-mentioned triglyceride of glycerin and fatty acid, when the total carbon number of the fatty acid is about 12 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

The above-mentioned triglyceride of glycerin and fatty acid is a so-called fat, and since it is a component which constitutes a human body, it is preferable from a viewpoint of safety.

As a commercial product of the above-mentioned triglyceride of glycerin and fatty acid, there are three coconut oil fatty acid glycerides, NA36, Panasate 800, Panasate 800B and Panasate 810S, and three C2L oil fatty acid glycerides and tri-CL oil fatty acid glycerides (manufactured by Nippon Oil Co., Ltd.) and the like can be exemplified.

The above diglycerides of glycerol and fatty acid are also called diglycerides, such as diesters of glycerol and decanoic acid (C ₁₀ ), diesters of glycerol and dodecanoic acid (C ₁₂ ), glycerol and palmitic acid (C _The diester of ₁₆ ), the diester of glycerin and two kinds of fatty acids, and a mixture thereof may be mentioned.

In the diester of the glycerin and the fatty acid, the carbon number of the fatty acid constituting the diester of glycerin and the fatty acid is a total of, that is, for the formula (6), when the total carbon number of the R ⁵ C and R ⁶ C moieties is 16, the IOB is 0.58. Therefore, in the diester of the glycerin and the fatty acid, when the total carbon number of the fatty acid is about 16 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

The monoester of the above glycerin and a fatty acid is also called a monoglyceride, for example, a octadecanoic acid (C ₁₈ ) monoester of glycerin, a behenic acid (C ₂₂ ) monoester of glycerin, etc. are mentioned.

In the monoester of the glycerin and the fatty acid, the carbon number of the fatty acid constituting the monoester of glycerin and the fatty acid, that is, for the formula (7), when the carbon number of the R ⁵ C moiety is 19, the IOB is 0.59. Therefore, in the monoester of the above glycerin and fatty acid, when the carbon number of the fatty acid is about 19 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

[(A ₃ ) ester of chain hydrocarbon diol and fatty acid]

As the ester of the above chain hydrocarbon diol and a fatty acid, for example, a C ₂ -C ₆ chain hydrocarbon diol, such as a C ₂ -C ₆ glycol, such as ethylene glycol, propylene glycol, butylene glycol, pentanediol or Monoesters or diesters of hexanediol and fatty acids are exemplified.

Specifically, as the ester of the above chain hydrocarbon diol and a fatty acid, for example, the following formula (8): R ⁸ COOC _k H _2k OCOR ⁹ (8)

(wherein k is an integer from 2 to 6, and R ⁸ and R ^{9 are} each a chain hydrocarbon)

a diester of a C ₂ -C ₆ glycol and a fatty acid, and the following formula (9): R ⁸ COOC _k H _2k OH (9)

(where k is an integer from 2 to 6, and R ⁸ is a chain hydrocarbon)

The monoester of C ₂ -C ₆ glycol and fatty acid can be mentioned.

Among the above-mentioned esters of C ₂ -C ₆ glycol and fatty acid, as a fatty acid which must be esterified (corresponding to R ⁸ COOH and R ⁹ COOH for formula (8) and formula (9)), if C ₂ ~ C ₆ The ester of an alcohol and a fatty acid may satisfy the above requirements of the IOB, the melting point and the water solubility, and is not particularly limited. For example, the fatty acid listed in the "(A ₁ ) chain hydrocarbon tetraol and fatty acid ester", that is, a saturated fatty acid The unsaturated fatty acid is preferably a saturated fatty acid in consideration of the possibility of modification by oxidation or the like.

In the diester of the butanediol (k=4) and the fatty acid represented by the formula (8), when the total carbon number of the R ⁸ C and R ⁹ C moieties is 6, the IOB is 0.6. Therefore, in the diester of the butanediol (k=4) represented by the formula (8) and the diester of the fatty acid, when the total carbon number is about 6 or more, the requirement that the IOB is from about 0 to about 0.6 is satisfied. Further, in the monoester of ethylene glycol (k=2) and the fatty acid represented by the formula (9), when the carbon number of the R ⁸ C moiety is 12, the IOB is 0.57. Therefore, in the monoester of the ethylene glycol (k=2) and the fatty acid represented by the formula (9), when the carbon number of the fatty acid is about 12 or more, the requirement of IOB of from about 0 to about 0.6 is satisfied.

Examples of the C ₂ ~ C ₆ glycol esters of fatty acids and, considering the possibility of modification performed by oxidation and other saturated fatty acids from C ₂ ~ C ₆ glycol ester of a fatty acid, i.e., C ₂ ~ C ₆ Glycol and saturated fatty acid esters are preferred.

Further, as the ester of the C ₂ -C ₆ glycol and the fatty acid, when the IOB is to be made smaller and further hydrophobic, the ester of the glycol having a large carbon number and the fatty acid, for example, from butanediol, An ester of a glycol or a fatty acid of pentanediol or hexanediol is preferred.

Further, as the ester of the C ₂ -C ₆ glycol and the fatty acid, when the IOB is to be made smaller to make it more hydrophobic, it is preferred to use a diester.

Commercial products such as compole BL and combole BS (manufactured by Nippon Oil Co., Ltd.) and the like are exemplified as the commercial products of the above-mentioned esters of C ₂ to C ₆ glycols and fatty acids.

[(B) an ether having a compound having 2 to 4 hydroxyl groups and a compound having 1 hydroxyl group]

(B) a compound having 2 to 4 hydroxyl groups and an ether having a compound having one hydroxyl group (hereinafter sometimes referred to as "compound (B)") contains a compound having 4, 3 or 2 hydroxyl groups and having The ether of one hydroxy compound has only the above-mentioned range of IOB, melting point and water solubility, and all of the hydroxyl groups may not be etherified.

Examples of the compound having the above 2 to 4 hydroxyl groups include those of the "compound (A)", such as pentaerythritol, glycerin, and glycol.

As the above compound having one hydroxyl group, for example, a compound in which one hydrogen atom of a hydrocarbon may be substituted by one hydroxyl group (-OH), for example, an aliphatic monohydric alcohol, such as a saturated aliphatic monohydric alcohol and an unsaturated aliphatic monohydric alcohol Alcohols can be mentioned.

The saturated aliphatic monohydric alcohol, for example, a C ₁ to C ₂₀ saturated aliphatic monohydric alcohol, for example, methyl alcohol (C ₁ ) (C ₁ represents a carbon number, the same applies hereinafter), ethyl alcohol (C ₂ ), Propyl alcohol (C ₃ ) and isomers thereof, such as isopropyl alcohol (C ₃ ), butyl alcohol (C ₄ ) and isomers thereof, such as sec-butyl alcohol (C ₄ ) and tert-butyl Alcohol (C ₄ ), pentyl alcohol (C ₅ ), hexyl alcohol (C ₆ ), heptyl alcohol (C ₇ ), octyl alcohol (C ₈ ) and isomers thereof, such as 2-ethylhexyl alcohol (C _8), nonyl alcohol (C _9), decyl alcohol (C _10), dodecyl alcohol (C _12), tetradecyl alcohol (C _14), cetyl (C _16), Heptadecyl alcohol (C ₁₇ ), stearyl alcohol (C ₁₈ ), and eicosyl alcohol (C ₂₀ ), and the isomers not enumerated thereof may be mentioned.

In the unsaturated aliphatic monohydric alcohol, one of the CC single bonds of the saturated aliphatic monohydric alcohol is replaced by a C=C double bond, and examples of the oleyl alcohol include, for example, a new Japanese physicochemical company. The purchased Riker series and the An Jieke series.

As the compound (B), for example, an ether of a (B ₁ ) chain hydrocarbon tetraol and an aliphatic monohydric alcohol, for example, a monoether, a diether, a triether, and a tetraether, preferably a diether, a triether, and a tetraether, More preferably, it is a triether and a tetraether, and most preferably an ether of a tetraether, a (B ₂ ) chain hydrocarbon triol and an aliphatic monohydric alcohol, such as a monoether, a diether and a triether, preferably a diether and The triether, more preferably a triether, and an ether of a (B ₃ ) chain hydrocarbon diol and an aliphatic monohydric alcohol, such as a monoether and a diether, and preferably a diether may be mentioned.

As the ether of the chain hydrocarbon tetraol and the aliphatic monohydric alcohol, for example, the following formulas (10) to (13):

(wherein R ¹⁰ to R ^{13 are} each a chain hydrocarbon.)

The pentaerythritol and the tetraether, triether, diether and monoether of the aliphatic monohydric alcohol are exemplified.

As the ether of the above chain hydrocarbon triol and the aliphatic monohydric alcohol, for example, the following formulas (14) to (16):

(wherein R ¹⁴ to R ^{16 are} each a chain hydrocarbon.)

The triglyceride, the diether and the monoether of the glycerin and the aliphatic monohydric alcohol are exemplified.

As the ether of the above-mentioned chain hydrocarbon diol and aliphatic monohydric alcohol, there is the following formula (17): R ¹⁷ OC _n H _2n OR ¹⁸ (17)

(wherein n is an integer from 2 to 6, and R ¹⁷ and R ^{18 are} each a chain hydrocarbon)

a diether of a C ₂ -C ₆ glycol and an aliphatic monohydric alcohol, and the following formula (18): R ¹⁷ OC _n H _2n OH (18)

(wherein n is an integer from 2 to 6, and R ¹⁷ is a chain hydrocarbon)

The monoether of C ₂ -C ₆ glycol and aliphatic monohydric alcohol can be exemplified.

In the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, that is, R ¹⁰ , R ¹¹ , R for the above formula (10) ^{When the} total carbon number of the ¹² and R ¹³ portions is 4, the IOB becomes 0.44. Therefore, in the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, when the total number of carbon atoms of the aliphatic monohydric alcohol is about 4 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

In the triether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the triether of the pentaerythritol and the aliphatic monohydric alcohol, that is, R ¹⁰ , R ¹¹ and R for the above formula (11) ^The total carbon number of the ¹² parts is 9 when the IOB becomes 0.57. Therefore, when the total number of carbon atoms of the aliphatic monohydric alcohol in the above-mentioned pentaerythritol and the aliphatic trihydric alcohol is about 9 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

In the diether of the pentaerythritol and the aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the diether of the pentaerythritol and the aliphatic monohydric alcohol is the same as the above formula (12), R ¹⁰ and R ¹¹ When the total carbon number is 15, the IOB becomes 0.60. Therefore, when the total number of carbon atoms of the aliphatic monohydric alcohol in the diether of the pentaerythritol and the aliphatic monohydric alcohol is about 15 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

In the monoether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of the pentaerythritol and the aliphatic monohydric alcohol, that is, the carbon number of the R ¹⁰ moiety in the above formula (13) is 22 The IOB becomes 0.59. Therefore, in the monoether of the pentaerythritol and the aliphatic monohydric alcohol, when the carbon number of the aliphatic monohydric alcohol is about 22 or more, the requirement of IOB of from about 0 to about 0.6 is satisfied.

Further, in the triether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the triether of the glycerin and the aliphatic monohydric alcohol is a total of the formula (14), R ¹⁴ and R ¹⁵ and When the total carbon number of the R ¹⁶ portion is 3, the IOB becomes 0.50. Therefore, when the total carbon number of the aliphatic monohydric alcohol in the triglyceride of the aliphatic glycerol and the aliphatic monohydric alcohol is about 3 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

In the diether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the diether of glycerin and the aliphatic monohydric alcohol, that is, the carbon of the formula (15), R ¹⁴ and R ¹⁵ When the total number is 9, the IOB becomes 0.58. Therefore, when the total carbon number of the aliphatic monohydric alcohol in the diglyceride of the glycerin and the aliphatic monohydric alcohol is about 9 or more, the requirement of IOB of about 0 to about 0.6 is satisfied.

In the monoether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of glycerin and the aliphatic monohydric alcohol, that is, when the carbon number of the R ¹⁴ moiety is 16 for the formula (16) The IOB became 0.58. Therefore, in the monoether of the above glycerin and the aliphatic monohydric alcohol, when the carbon number of the aliphatic monohydric alcohol is about 16 or more, the requirement of IOB of from about 0 to about 0.6 is satisfied.

In the diether of the butanediol (n=4) represented by the formula (17) and the diester of the aliphatic monohydric alcohol, when the total carbon number of the R ¹⁷ and R ¹⁸ moieties is 2, the IOB is 0.33. Therefore, in the diether of the butanediol (n=4) represented by the formula (17) and the diester of the aliphatic monohydric alcohol, when the total carbon number of the aliphatic monohydric alcohol is 2 or more, the requirement of the IOB of about 0 to about 0.6 is satisfied. . Further, in the monoether of ethylene glycol (n = 2) represented by the formula (18) and the aliphatic monohydric alcohol, when the carbon number of the R ¹⁷ moiety is 8, the IOB is 0.60. Therefore, in the monoether of ethylene glycol (n=2) represented by the formula (18) and the aliphatic monohydric alcohol, when the carbon number of the aliphatic monohydric alcohol is about 8 or more, the requirement of IOB of from about 0 to about 0.6 is satisfied.

The compound (B) can be produced by dehydrating and condensing a compound having 2 to 4 hydroxyl groups and a compound having one hydroxyl group such as an aliphatic monohydric alcohol in the presence of an acid catalyst.

[(C) an ester of a compound having 2 to 4 carboxyl groups and a compound having 1 hydroxyl group]

(C) an ester having a compound having 2 to 4 carboxyl groups and an ester having a compound having one hydroxyl group (hereinafter sometimes referred to as "compound (C)") and a compound having 4, 3 or 2 carboxyl groups; An ester of a compound having one hydroxyl group is only in the range of the above IOB, melting point and water solubility, and all of the carboxyl groups need not be esterified.

As the compound having the above 2 to 4 carboxyl groups, for example, a chain hydrocarbon having 2 to 4 carboxyl groups, for example, a chain hydrocarbon dicarboxylic acid such as an alkanedicarboxylic acid such as ethanedioic acid, propane diacid, butane 2 Acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, decanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acid, such as an alkanetricarboxylic acid, such as propane tricarboxylic acid, Butane triacid, pentane tricarboxylic acid, hexane tricarboxylic acid, heptane triacid, octane tricarboxylic acid, decane tricarboxylic acid and decane tricarboxylic acid, and chain hydrocarbon tetracarboxylic acid, such as an alkane tetracarboxylic acid, for example Butane tetracarboxylic acid, pentanetetracarboxylic acid, hexanetetracarboxylic acid, heptanetetracarboxylic acid, octane tetracarboxylic acid, decanetetracarboxylic acid, and decanetetracarboxylic acid are exemplified.

Further, the compound having the above 2 to 4 carboxyl groups contains a hydroxy acid having 2 to 4 carboxyl groups, and examples thereof include malic acid, tartaric acid, citric acid, isocitric acid, and the like, and an alkoxy group having 2 to 4 carboxyl groups. Examples of the acid, for example, O-acetyl citrate, and an oxo acid having 2 to 4 carboxyl groups.

As the compound having one hydroxyl group, those listed in the item of "compound (B)", for example, an aliphatic monohydric alcohol can be mentioned.

As the compound (C), (C ₁ ) a chain hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxy acid, an alkoxy acid or an ester of an oxo acid and an aliphatic monohydric alcohol, such as a monoester, a diester or a triester And a tetraester, preferably a diester, a triester and a tetraester, more preferably a triester and a tetraester, more preferably a tetraester, (C ₂ ) a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid An alkoxy acid or an ester of an oxo acid with an aliphatic monohydric alcohol, such as a monoester, a diester or a triester, preferably a diester and a triester, more preferably a triester, and (C ₃ ) has 2 The ester of a carboxyl group of a hydrocarbon hydrocarbon dicarboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid and an aliphatic monohydric alcohol, for example, a monoester or a diester, is preferably a diester.

Examples of the compound (C) include dioctyl adipate, diisostearyl malate, tributyl citrate, and tributyl butyl acetoate, which are commercially available.

[(D) in the hydrocarbon insertion of any one selected from the group consisting of an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonate bond (-OCOO-) Compound]

(D) inserting into the hydrocarbon a group selected from the group consisting of an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonate bond (-OCOO-) One compound (hereinafter sometimes referred to as "compound (D)"), (D ₁ ) an aliphatic monohydric alcohol and an aliphatic monohydric alcohol ether, (D ₂ ) dialkyl ketone, (D ₃ ) fatty acid The ester with an aliphatic monohydric alcohol and the (D ₄ ) dialkyl carbonate are mentioned.

[(D ₁ ) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol]

As the ether of the above aliphatic monohydric alcohol and aliphatic monohydric alcohol, there is the following formula (19): R ¹⁹ OR ²⁰ (19)

(wherein R ¹⁹ and R ^{20 are} each a chain hydrocarbon)

The compound can be exemplified.

The aliphatic monohydric alcohol constituting the ether (corresponding to R ¹⁹ OH and R ²⁰ OH in the formula (19)), the ether is not particularly limited as long as it satisfies the requirements of the above IOB, melting point and water solubility. For example, the aliphatic monohydric alcohols listed in the item of "compound (B)" can be mentioned.

In the ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the ether is that when the total number of carbon atoms in the R ¹⁹ and R ²⁰ moieties is 2 in the above formula (19) Since the IOB becomes 0.50, the above IOB requirement can be satisfied if the total number of carbon atoms is about 2 or more. However, the total carbon number is about 6 and the water solubility is about 2 g, which is also problematic from the viewpoint of vapor pressure. When the water solubility is required to satisfy the requirements of about 0.05 g or less, it is preferred that the total carbon number is about 8 or more.

[(D ₂ ) dialkyl ketone]

As the above dialkyl ketone, there is the following formula (20): R ²¹ COR ²² (20)

(wherein R ²¹ and R ^{22 are} each an alkyl group)

The compound can be exemplified.

In the above dialkyl ketone, when the total number of carbon atoms of R ²¹ and R ²² is 5 and the IOB is 0.54, the total number of carbon atoms is about 5 or more, which satisfies the requirements of the above IOB. However, in the total of the above carbon numbers, the water solubility is a high value of about 2 g. Therefore, in order to satisfy the requirement of water solubility of about 0.05 g or less, it is preferred that the total carbon number is about 8 or more. Further, in consideration of the vapor pressure, the carbon number is preferably about 10 or more, and about 12 or more is preferable.

Further, when the total carbon number is about 8, for example, 5-nonanone has a melting point of about -50 ° C and a vapor pressure of about 230 Pa at 20 ° C.

The above-mentioned dialkyl ketone can be obtained by a known method, for example, by oxidizing a second-stage alcohol with chromic acid or the like by a known method.

[(D ₃ ) ester of fatty acid with aliphatic monohydric alcohol]

As an ester of the above fatty acid and an aliphatic monohydric alcohol, for example, the following formula (21): R ²³ COOR ²⁴ (21)

(wherein R ²³ and R ^{24 are} each a chain hydrocarbon)

The compound can be exemplified.

The fatty acid constituting the above-mentioned ester (corresponding to R ²³ COOH in the formula (21)), for example, the fatty acid listed in the "(A ₁ ) chain hydrocarbon tetraol and fatty acid ester", that is, a saturated fatty acid or an unsaturated fatty acid It is preferable to use a saturated fatty acid in consideration of the possibility of modification by oxidation or the like. The aliphatic monohydric alcohol constituting the above-mentioned ester (corresponding to R ²⁴ OH for the formula (21)), for example, the aliphatic monohydric alcohol listed in the item of the "compound (B)" can be mentioned.

Further, in the ester of the fatty acid and the aliphatic monohydric alcohol, the carbon number of the fatty acid and the aliphatic monohydric alcohol is the total, that is, for the formula (21), the total number of carbons of the R ²³ C and R ²⁴ portions is 5 when the IOB is In the ester of the above fatty acid and the aliphatic monohydric alcohol, the total number of carbon atoms in the R ²³ C and R ²⁴ moieties is about 5 or more, and the above-mentioned IOB requirement is satisfied. However, for example, in the above-mentioned butyl acetate having a total carbon number of 6, the vapor pressure exceeds a high value of 2000 Pa. Therefore, in consideration of the vapor pressure, it is preferred that the total carbon number is about 12 or more. Further, if the total carbon number is about 11 or more, the requirement of water solubility of about 0.05 g or less can be satisfied.

As an example of the ester of the above fatty acid and an aliphatic monohydric alcohol, for example, an ester of dodecanoic acid (C ₁₂ ) with lauryl alcohol (C ₁₂ ), tetradecanoic acid (C ₁₄ ) and dodecyl alcohol (C ₁₂₎ esters and the like may be mentioned of, as the selling products of esters of fatty acids with aliphatic monohydric alcohols of, for example, ErekutolWE20, and ErekutolWE40 (as above NOF Co., Ltd.) may be mentioned.

[(D ₄ ) dialkyl carbonate]

As the above dialkyl carbonate, there is the following formula (22): R ²⁵ OC(=O)OR ²⁶ (22)

(wherein R ²⁵ and R ^{26 are} each an alkyl group)

The compound can be exemplified.

In the above dialkyl carbonate, when the total carbon number of R ²⁵ and R ²⁶ is 6, the IOB is 0.57, and when the total carbon number of R ²⁵ and R ²⁶ is about 6 or more, the requirement of IOB is satisfied.

When the water solubility is considered, the total carbon number of R ²⁵ and R ²⁶ is preferably about 7 or more, and about 9 or more is preferable.

The above dialkyl carbonates can be synthesized by the reaction of phosgene with an alcohol, the reaction of a chlorinated acid ester with an alcohol or an alcoholate, and the reaction of silver carbonate with an alkyl iodide, in addition to being commercially available.

[(E) Poly C ₂ ~C ₆ alkanediol, or its ester or ether]

As the above-mentioned poly C ₂ -C ₆ alkanediol, or an ester or ether thereof (hereinafter sometimes referred to as compound (E)), (E ₁ ) poly C ₂ -C ₆ alkanediol, (E ₂ ) poly C ₂ ~C ₆ alkanediol and fatty acid ester, (E ₃ ) poly C ₂ ~ C ₆ alkanediol and aliphatic monohydric alcohol ether, (E ₄ ) poly C ₂ ~ C ₆ alkanediol and chain hydrocarbon An ester of a tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid or a chain hydrocarbon dicarboxylic acid, and (E ₅ ) a poly C ₂ -C ₆ alkanediol with a chain hydrocarbon tetraol, a chain hydrocarbon triol, or a chain The ether of a hydrocarbon diol is mentioned. As explained below.

[(E ₁ )Poly C ₂ ~C ₆ alkanediol]

(E ₁ ) The poly C ₂ -C ₆ alkanediol contains not only a homopolymer of a single glycol but also a copolymer of two or more kinds of glycols and a random polymer. Examples of the glycolic acid include a C ₂ -C ₆ alkanediol, that is, ethylene glycol, propylene glycol, butanediol, pentanediol, or hexanediol. As the above-mentioned glycol species, from the viewpoint of reducing the IOB of the poly C ₂ -C ₆ alkanediol, it is preferred to use propylene glycol, butanediol, pentanediol or hexanediol, and butanediol and pentanediol. Or hexylene glycol is preferred.

In the present specification, the "poly C ₂ -C ₆ alkanediol" is a C ₂ -C ₆ alkanediol, which may be selected from the group consisting of ethylene glycol, propylene glycol, butanediol, pentanediol, and hexanediol. Any of a group of homopolymers, two or more kinds of copolymers selected from the above group, or two or more kinds of random polymers selected from the above group.

When the poly C ₂ -C ₆ alkanediol is a homopolymer, the poly C ₂ -C ₆ alkanediol is represented by the following formula (23): HO-(C _m H _2m O) _n -H (23)

Shown.

Further, as a result of the inventors' confirmation, when polyethylene glycol (when the formula (23) corresponds to m=2) is n≧45 (about 2,000 molecular weights), the requirements of the IOB satisfying about 0 to about 0.60 are satisfied. However, even if the molecular weight exceeds 4,000, the water solubility requirement cannot be met. Therefore, considering that (E ₁ ) a poly-C ₂ -C ₆ alkanediol does not contain a homopolymer of ethylene glycol, ethylene glycol as a copolymer with other glycols or a random polymer must be contained in (E) ₁ ) Poly C ₂ ~C ₆ alkanediol.

Therefore, the homopolymer of the formula (23) contains a homopolymer of propylene glycol, butylene glycol, pentanediol or hexanediol.

From the above, it is known that for the formula (23), m is from about 3 to about 6, and from about 4 to about 6 is preferred, and n is 1 or more.

For the above formula (23), the value of n is, for example, an IOB having a poly C ₂ -C ₆ alkanediol of from about 0 to about 0.60, a melting point of about 45 ° C or less, and about 0.05 g or less of 100 g of water for 25 ° C. The value of water solubility.

For example, when the formula (23) is polypropylene glycol (m=3), the IOB is 0.58 at n=12. Therefore, when the formula (23) is polypropylene glycol (m = 3), the requirement of the above IOB is satisfied when m≧ is about 12.

Further, when the formula (21) is polytetramethylene glycol (m = 4), the IOB is 0.57 at n = 7. Therefore, when the formula (23) is polytetramethylene glycol (m=4), the requirement of the above IOB is satisfied when n≧ is about 7.

From the viewpoints of OB, melting point and water solubility, the weight average molecular weight of the poly C _4-6 alkanediol is preferably from about 200 to about 10,000, more preferably from about 250 to about 8,000, and most preferably from about 250 to about A range of 5,000.

Further, from the viewpoints of OB, melting point and water solubility, the weight average molecular weight of the poly C ₃ alkanediol, i.e., polypropylene glycol, is preferably from about 1,000 to about 10,000, more preferably from about 3,000 to about 8,000, and most preferably A range of about 4,000 to about 5,000. When the weight average molecular weight is less than about 1,000, the water solubility is not satisfied, and the weight average molecular weight is larger, and particularly the absorption speed of the absorber and the whiteness of the surface sheet tend to increase.

As a commercial product of the above poly C ₂ -C ₆ alkanediol, for example, You You Lu (trademark) D-1000, D-1200, D-2000, D-3000, D-4000, PB-500, PB-700 PB-1000 and PB-2000 (above are manufactured by Nippon Oil Co., Ltd.) can be cited.

[(E ₂ ) Poly C ₂ ~ C ₆ alkanediol and ester of fatty acid]

As the ester of the poly C ₂ -C ₆ alkanediol and the fatty acid, there is an OH terminal of the poly C ₂ -C ₆ alkanediol described in the item "(E ₁ ) poly C ₂ -C ₆ alkanediol" One or both of the esterified fatty acids, that is, monoesters and diesters may be mentioned.

For the ester of a poly C ₂ -C ₆ alkanediol and a fatty acid, as a fatty acid which must be esterified, for example, a fatty acid listed as "(A ₁ ) chain hydrocarbon tetraol and a fatty acid ester", that is, a saturated fatty acid or not The saturated fatty acid is preferably a saturated fatty acid in consideration of the possibility of modification by oxidation or the like.

A commercially available product of the above-mentioned ester of a poly C ₃ -C ₆ alkanediol and a fatty acid, for example, WILBRIDE cp9 (manufactured by Nippon Oil Co., Ltd.) can be mentioned.

[(E ₃ ) poly C ₂ ~ C ₆ alkanediol and ether of aliphatic monohydric alcohol]

Examples of an ether poly C ₂ ~ C ₆ alkylene glycol and the aliphatic monohydric alcohol, with a "(E ₁₎ a poly C ₂ ~ C ₆ alkylene glycol" is the item described poly C ₂ ~ C ₆ alkanediol One or both of the OH ends may be etherified by an aliphatic monohydric alcohol, and monoethers and diethers may be mentioned.

For the ether of poly C ₂ -C ₆ alkanediol and aliphatic monohydric alcohol, as the aliphatic monohydric alcohol which must be etherified, for example, the aliphatic monohydric alcohol listed in the item "Compound (B)" may be used. Give it.

[(E ₄ ) an ester of a poly C ₂ -C ₆ alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid or a chain hydrocarbon dicarboxylic acid]

An ester of the above poly C ₂ -C ₆ alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid or a chain hydrocarbon dicarboxylic acid, as a poly C ₂ -C ₆ alkanediol which must be esterified, there "(E ₁₎ a poly C ₂ ~ C ₆ alkanediol" item of the described poly C ₂ ~ C ₆ alkanediol include. Further, as a chain hydrocarbon dcarboxylic acid, a chain hydrocarbon tricarboxylic acid, and a chain hydrocarbon dicarboxylic acid which are required to be esterified, there is a description of the item "compound (C)".

The ester of the above poly C ₂ -C ₆ alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid or a chain hydrocarbon dicarboxylic acid may be obtained by a chain hydrocarbon tetracarboxylic acid or a chain, in addition to being commercially available. The hydrocarbon tricarboxylic acid or the chain hydrocarbon dicarboxylic acid is produced by polycondensing a C ₂ -C ₆ alkanediol under known conditions.

[(E ₅ ) poly C ₂ ~ C ₆ alkanediol and chain hydrocarbon tetraol, chain hydrocarbon triol, or ether of chain hydrocarbon diol]

The above-mentioned poly C ₂ -C ₆ alkanediol and a chain hydrocarbon tetraol, a chain hydrocarbon triol, or a chain hydrocarbon diol are contained as a poly C ₂ -C ₆ alkanediol which must be etherified. (E ₁₎ a poly C ₂ ~ C ₆ alkanediol item "of the described poly C ₂ ~ C ₆ alkanediol include. Further, as a chain hydrocarbon tetraol, a chain hydrocarbon triol, and a chain hydrocarbon diol which are required to be etherified, there are items described as "compound (A)", and examples thereof include pentaerythritol, glycerin, and glycol. .

As a commercial product of the above-mentioned poly C ₂ -C ₆ alkanediol and a chain hydrocarbon tetraol, a chain hydrocarbon triol, or a chain hydrocarbon diol, for example, You Lupu (trademark) 5TP-300KB, and excellent You can mention the European road (trademark) TG-3000 and TG-4000 (made by Nippon Oil Co., Ltd.).

Youlupu (trademark) 5TP-300KB is a compound of pentaerythritol 1 mole condensation polymerization propylene glycol 65 moles and ethylene glycol 5 moles, the IOB is 0.39, the melting point is less than 45 ° C, and the water solubility is less than 0.05. g.

Youyou Ou Lu (trademark) TG-3000 is a compound of 50 moles of condensed propylene glycol in glycerol 1 molar. The IOB is 0.42, the melting point is less than 45 ° C, the water solubility is less than 0.05g, and the weight average molecular weight is About 3,000.

Youyou Ou Lu (trademark) TG-4000 is a compound of glycerol 1 mole condensation propylene glycol 70 mole, the IOB is 0.40, the melting point is less than 45 ° C, the water solubility is less than 0.05g, and the weight average molecular weight is about 4,000.

An ether of the above poly C ₂ -C ₆ alkanediol and a chain hydrocarbon tetraol, a chain hydrocarbon triol, or a chain hydrocarbon diol. Further, it can be produced by subjecting a C ₂ -C ₆ alkanediol to polycondensation under a known condition by a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain hydrocarbon diol.

[(F) chain hydrocarbon]

The above-mentioned chain hydrocarbon has a minerality value of 0, an IOB of 0, and a water solubility of almost 0 g. Therefore, the above-mentioned blood modifying agent can be contained only in a melting point of about 45 ° C or lower. Examples of the chain hydrocarbons include, for example, a (F ₁ ) chain alkane, for example, a linear alkane or a branched alkane. For example, in the case of a linear alkane, when the melting point is about 45° C. or less, the carbon number is substantially 22 or less. By. Further, in consideration of the vapor pressure, it basically contains a carbon number of 13 or more. In the case of a branched alkane, the number of carbon atoms is 22 or more for the same carbon number because the melting point is lower than the case of the linear alkane. As a commercial product of the above-mentioned hydrocarbon, for example, PARLEAM6 (Nippon Oil Co., Ltd.) can be mentioned.

Although the blood modifying agent described above is discussed in detail at the same time as the examples, it is considered to have a mechanism for lowering blood viscosity and surface tension. The menstrual blood absorbed by the absorbent article is compared with the general blood, and contains proteins such as the endometrial wall, and these blood cells have a function as a link, and it is easy to become a state in which the blood cells are in a string. Therefore, the menstrual blood absorbed by the absorbent article tends to be highly viscous. If the surface layer is non-woven, the menstrual blood tends to block between the fibers, and the wearer tends to feel a sticky feeling, and the menstrual sheet surface diffuses on the surface of the surface sheet. Easy to leak.

In the absorbent article disclosed by the present invention, the surface layer sheet contains a blood modifying agent which has a mechanism for lowering blood viscosity and surface tension, and is not easily blocked by menstrual blood between the fibers of the surface layer sheet, and the menstrual blood can rapidly self-surface layer. The sheet moves to the absorber.

Further, in the absorbent article according to the present invention, since the melting point of the blood modifying agent is about 45 ° C or lower, it is liquid or solid at normal temperature (25 ° C), and is in contact with body fluid of about 30 to about 40 ° C. Liquefaction (or liquid), easy to dissolve in body fluids.

Moreover, the blood modifying agent with an IOB of about 0 to about 0.60 has high organicity and is easily buried between the blood cells, so that the blood cells can be stabilized, and the blood cells are not easy. Form a string structure.

The above-mentioned modifier is capable of stabilizing the blood cells and making the blood cells less likely to form a string structure, so that the absorber easily absorbs menstrual blood. For example, in an acrylic high-absorbent polymer, an absorbent article containing SAP, when the menstrual blood is absorbed, the blood cell of the string covers the surface of the SAP, so that the absorption performance of the SAP is not easily exhibited, but it is stabilized. Blood cells can make SAP's absorption performance easy to play. Moreover, the blood modifying agent having high affinity with red blood cells prevents the red blood cells from being damaged due to the protection of the red blood cell membrane.

In the above absorbent article, the surface layer sheet preferably contains the blood modifying agent in an amount of from about 1 to about 30 g/m ² , more preferably from about 2 to about 20 g/m ² , most preferably from about 3 to about 10 g/m ² . The basis weight range. When the basis weight of the blood modifying agent is lower than about 1 g/m ² , the blood reforming effect tends to be insufficient, and if the basis weight of the blood modifying agent is too large, the stickiness during use may increase. tendency.

The method for applying the blood modifying agent is not particularly limited, and may be heated if necessary, for example, by a non-contact coating machine such as a spiral coater, a curtain coater, a spray coater, or a dip coating. Coating by a machine or the like, a contact coater or the like. A non-contact coater is preferred because the droplet-shaped or particulate-shaped modifier can be uniformly dispersed throughout the entire material and does not cause damage to the material. Further, the blood modifying agent may be heated directly at a room temperature or heated to reduce the viscosity, and when it is solid at room temperature, it may be heated to a liquefaction and then coated using a controlled slit HMA gun. The microparticle-shaped blood modifying agent can be applied by increasing the air pressure of the controlled slit HMA gun.

The above blood modifying agent can be applied at the time of producing a surface sheet or coated on a production line for producing an absorbent article. Investment by suppression equipment From the point of view, it is better to apply a blood modifying agent to the production line of the absorbent article, and to inhibit the blood modifying agent from falling off and contaminating the production line, in the downstream step of the production line, specifically before sealing the product into each package, Cloth blood modifier is preferred.

The surface sheet may be coated with a hydrophilic agent or may be hydrophilized after mixing. When the original material has hydrophilicity and has an IOB of about 0 to about 0.60, the lipophilic region and the hydrophilic region become sparsely coherent when a highly organic and lipophilic modifier is applied. Thereby, the menstrual blood formed by the hydrophilic component (plasma or the like) and the lipophilic component (such as blood cells) can exhibit a certain absorption performance.

The above blood modifying agent preferably has a weight average molecular weight of about 2,000 or less, and preferably has a weight average molecular weight of 1,000 or less. If the weight average molecular weight becomes high, the viscosity of the blood modifying agent is difficult to fall to a viscosity suitable for coating, and it must be diluted with a solvent. Further, if the number average molecular weight is increased, the blood modifying agent is debonded and causes an uncomfortable feeling to the user.

The back sheet 3 shown in Figs. 1 and 2 is a leakage of body fluid which is prevented from being absorbed by the absorber 4. In the back sheet 3, a material that does not penetrate the body fluid is used. For example, as the back sheet 3, a water-repellent non-woven fabric, a water-impermeable plastic film such as polyethylene or polypropylene, a laminate sheet of a non-woven fabric and a water-impermeable plastic film, or the like is used. Further, it is preferable to use an SMS non-woven fabric in which a melt-resistant nonwoven fabric having a high water resistance is sandwiched by a spunbonded nonwoven fabric having high strength as the back sheet 3. When a material having a gas permeable property that does not pass through a body fluid is used as the back sheet 3, leakage at the time of use can be reduced.

The absorber 4 absorbs body fluid and holds it. The absorbent body 4 is high in volume, and the shape is not easily broken, and it is preferable that the chemical stimulation is less. For example, as the absorbent body 4, a composite absorbent body composed of a fluffy wood pulp or an air laid-laid fiber nonwoven fabric and a superabsorbent polymer (SAP) can be used. The composite absorbent body may be covered with a liquid permeable material such as toilet paper.

Further, in place of the fluffy wood pulp of the composite absorbent body, for example, artificial cellulose fibers such as chemical wood pulp, cellulose fibers, hydrazine, and acetate may be used. The basis weight of the absorbent fiber such as wood pulp in the composite absorbent body is preferably 100 g/m ² or more and 800 g/m ² or less, and the mass ratio of the superabsorbent polymer in the composite absorbent body is such that the absorbent fiber is used. When it is 100%, it is preferably 10% or more and 65% or less. The basis weight of the liquid permeable material covering the toilet paper or the like of the composite mixture is preferably 12 g/m ² or more and 30 g/m ² or less.

As the air-laid fiber nonwoven fabric of the above composite composite, for example, a non-woven fabric in which a non-woven fabric or a wood pulp and a synthetic fiber are fixed by a binder is used after heat-melting the wood pulp and the synthetic fiber.

The superabsorbent polymer of the above composite absorbent is a three-dimensional mesh structure having a water-soluble polymer and moderately cross-linking. The absorbent polymer absorbs 30 to 60 times of water for the volume of the absorbent polymer before absorption of water. However, the absorbent polymer is water insoluble in nature. Further, even if the absorbent polymer is applied with a large amount of pressure, the absorbed water does not escape. As the absorbent polymer, for example, a starch-based, acrylic or amino acid-based particulate or fibrous polymer is used.

The shape and structure of the absorbent body may be changed as necessary, and the total absorption amount of the absorbent body 4 must correspond to the design insertion amount and the absorbent article 1. Hope to use. Further, the size, absorption capacity, and the like of the absorber 4 vary depending on the application.

The wing portion 5 is provided in the absorbent article 1 in order to securely fix the absorbent article 1 to the undergarment. After the wing portion 5 is folded on the outer side of the undergarment, the adhesive portion 6 is attached to the crotch portion of the underwear to securely fix the absorbent article 1 to the undergarment.

The adhesive portion 6 is for fixing the absorbent article 1 to the crotch portion of the undergarment. As the adhesive for forming the adhesive portion 6, for example, any one of a styrene-based polymer, an adhesion-imparting agent, and a plasticizer can be used as a main component. Examples of the styrene-based polymer include a styrene-ethylene-butylene-styrene block copolymer, a styrene-butene polymer, a styrene-butene-styrene block copolymer, and a styrene-isobutylene. - A styrene copolymer or the like may be used alone or in combination of two or more kinds of polymers. Among them, a styrene-ethylene-butylene-styrene block copolymer is preferred from the viewpoint of good heat stability.

Further, as the adhesion-imparting agent and the plasticizer, it is preferred to use a solid organic compound at normal temperature. Examples of the adhesion-imparting agent include a C5-based petroleum resin, a C9-based petroleum resin, a dicyclopentadiene-based petroleum resin, a rosin-based petroleum resin, a polydecene resin, a terpene phenol resin, and the like, and a plasticizer, for example, Examples of the monomer plasticizer such as tricresyl phosphate, dibutyl phthalate or dioctyl phthalate include an ethylene polymer or a polymer plasticizer such as polyester.

The sealing portion 7 is formed on both sides in the longitudinal direction of the absorbent article 1 by joining the surface sheet 2 by hot embossing to the back sheet 3.

Next, a method of manufacturing a surface sheet according to an embodiment of the present invention will be described with reference to Fig. 4 . 4 is an explanatory view of a surface sheet manufacturing apparatus 100 used in the method of manufacturing the surface sheet 2 according to the embodiment of the present invention. The top sheet manufacturing apparatus 100 includes an extension tooth roll 130 and a blood modifier coating spray 140. Further, the method for producing the surface sheet 2 includes a step of preparing a composite sheet formed of a resin film layer and a fiber assembly layer, a gear stretching step, and a blood modifying agent application step.

In the step of preparing the composite sheet formed of the resin film layer and the fiber assembly layer, the composite sheet 103 supplied from the roll of the composite sheet (not shown) is supplied to the extension tooth roll 130. The composite sheet 103 is produced by, for example, pressing a resin sheet such as a toilet paper sheet (a sheet of toilet paper into a sheet) to form a laminate, and forming a resin film layer on the fiber sheet.

In the gear extending step, the extension sheet 130 is passed through the composite sheet 103 to form a ridge portion on the composite sheet 103, and an opening portion is formed in the resin film layer of the composite sheet. Fig. 5(a) is a view showing the upper tooth roll 131 of the extension tooth roll 130. Fig. 5(b) is an explanatory view showing the gear teeth 133 disposed on the outer peripheral surface of the upper tooth roll 131. The gear teeth 133 indicate that the upper toothed roller 131 extends in the circumferential direction. When the composite sheet 103 is extended by the tooth roll 130, the resin film 103 is prevented from being cut by the angle of the gear teeth 133, and the corners of the gear teeth 133 are chamfered into an R shape.

The width of the gear teeth 133 is, for example, 0.3 to 0.5 mm, and the distance between the adjacent gear teeth 133 is, for example, 1.0 to 1.2 mm. Further, since the lower stage tooth roll 132 of the tooth roll 130 has the same shape as the upper stage tooth roll 131, the detailed description of the lower stage tooth roll 132 will be omitted. The gear teeth 133 of the upper tooth roll 131 and the lower tooth roll 132 The length of the upper-stage toothed roller 131 in the portion where the gear teeth are engaged, that is, the bite depth, is, for example, 1.25 mm. The gap between the gear teeth 133 of the upper tooth roll 131 and the gear teeth of the lower tooth roll 132 when the gear teeth 133 of the upper tooth roll 131 and the gear teeth of the lower tooth roll 132 are engaged is, for example, 0.25 to 0.45 mm.

When the composite sheet 103 is extended by the tooth roll 130, the composite sheet 103 is bent in a slightly wavy shape and extends in the machine direction, and a plurality of ridge portions juxtaposed in the width direction are formed on the composite sheet 103.

Next, referring to Fig. 6, the principle of forming an opening in the resin film layer of the composite sheet 103 when the extending tooth roll 130 passes through the resin film 103 will be described. Moreover, the principle does not limit the invention.

The composite sheet 103 is extended by a portion 105 in which the gear teeth 133 of the upper-stage toothed rolls 131 are engaged with the gear teeth 134 of the lower-stage toothed rolls 132.

The fiber assembly layer is easily broken by the substrate, and the tensile strength of the fiber assembly layer is relatively low for the tensile strength of the resin film layer. When the composite sheet 103 is stretched until the fiber assembly layer is broken by the substrate, the resin film layer which is integrated in the portion where the tissue layer is broken by the substrate is also destroyed, and the opening is formed in the resin film layer.

In detail, the surface of the fiber assembly layer has low smoothness, and small irregularities are formed on the surface of the fiber assembly layer. Therefore, a stronger portion and a weaker portion of the adhesion force between the resin film layer and the fiber assembly layer are produced. The resin film layer having a strong adhesion to the fiber assembly layer is such that the resin film layer and the fiber assembly layer are integrated when the composite sheet 103 is stretched until the fiber assembly layer is broken by the substrate. Substrate destruction It is broken to form an opening. However, the resin film layer having a weaker adhesion to the fiber assembly layer is such that when the fiber assembly layer is broken by the substrate, when the composite sheet 103 is stretched, it is released from the fiber assembly layer, so that the fiber collection is exhibited. The state of the layer leaving. As a result, the portion of the resin film layer having a weak adhesion to the fiber assembly layer is not broken together with the substrate damage of the fiber assembly layer. Therefore, the opening of the resin film layer in the portion where the adhesion to the fiber assembly layer is weak is not formed. On the surface of the fiber assembly layer, an irregular large-sized opening portion is formed in the resin film layer due to irregularities formed as irregularities.

Thereby, an opening portion is formed in the composite sheet 103 at a portion 105 which is extended by the composite sheet 103. Thereby, the body liquid of the user can be quickly moved from the opening portion 34 of the resin film layer 31 to the fiber assembly layer 32, and the absorption of the body fluid from the opening portion 34 of the resin film layer 31 can be promoted.

The composite sheet 103 is less likely to extend in the portion 106 where the gear teeth 133 of the upper stage tooth roll 131 and the gear teeth 134 of the lower stage tooth roll 132 are not engaged. Therefore, in the composite sheet 103, the gear teeth 133 of the upper-stage toothed roller 131 and the gear teeth 134 of the lower-stage toothed roller 132 are in the unengaged portion 106, and even if the composite sheet 103 passes through the extending toothed roller 130, the opening portion is not formed.

The gear teeth 133 of the upper tooth roll 131 of the composite sheet 103 and the gear teeth 134 of the lower stage tooth roll 132 are unengaged portions 106 corresponding to the top 23 and the bottom portion 22 of the ridge portion 21 of the surface sheet 2 (see Fig. 3). The gear teeth 133 of the upper tooth roll 131 of the composite sheet and the gear teeth 134 of the lower tooth roll 132 correspond to the wall portion 24 of the ridge portion 21 of the surface sheet 2 (see Fig. 3). Therefore, at the top of the ridge portion 21 of the surface sheet 2 The bottom portion 22 and the bottom portion 22 have no opening portion 34, and the opening portion 34 is provided in the wall portion 24 of the protruding portion 21 of the surface sheet 2.

A microscope photograph of the skin side of the surface sheet in which the opening portion is formed in the resin film layer is shown in Fig. 7 . Fig. 7 (a) shows a skin side micrograph of a surface sheet in which a plurality of openings are arranged in the extending direction of the ridge portion. Fig. 7(b) shows a skin side micrograph of the surface sheet of the wall portion having the ridge portion of the opening. Fig. 7 (c) shows a microscopic photograph of the skin side of the surface sheet of the opening of the film resin layer.

A microscope photograph of the garment side of the surface sheet in which the opening of the resin film layer is formed is shown in Fig. 8. Fig. 8(a) shows a coating-side micrograph of the fiber-assembled layer broken by the substrate and the surface layer of the resin film layer forming the opening. Fig. 8(b) is a photograph showing a side view of the surface of the surface sheet of the fiber covering layer which is covered by the substrate and which covers the opening of the resin film layer.

In the blood modifying agent coating step, the blood modifying agent is applied to the side of the resin film layer of the gear-extending composite sheet 104 by using the blood modifying agent coating spray 140, and the blood is modified in the composite sheet 104. Qualitative layer. The coating amount of the blood modifying agent is preferably 0.5 g/m ² or more, more preferably 10.0 g/m ² or less, and more preferably 1.0 g/m ² or more and 6.0 g/m ² or less. The blood modifying agent may be entirely applied to the composite sheet 104, or the blood modifying agent may be applied to the composite sheet only in a region where the body fluid of the wearer corresponding to the absorbent article is discharged. Further, in the blood modifying agent application step, the blood modifying agent 141 is applied to the composite sheet 104 by spraying with the blood modifying agent coating spray 140, and may be coated by a printing method, a dipping method or the like. The cloth method applies a blood modifying agent to the composite sheet 104. In the blood modifying agent coating step, the blood modifying agent that has entered the fiber assembly layer 32 from the opening portion 34 covers the fibers of the fiber assembly layer 32 by applying the blood modifying agent to the composite sheet 104.

Further, in the blood modifying agent application step, the spray 140 is applied using a blood modifying agent, and the blood modifying agent may be further applied to the side of the fiber assembly layer of the gear-extending composite sheet 104. Thereby, the blood modifying agent can be applied to the entire fiber assembly layer, and the amount of menstrual blood remaining in the fiber collection layer can be further reduced.

The above description is only an example, and the present invention is not limited to the above embodiment.

Example

The invention is illustrated by the following examples, but the invention is not limited thereto.

By the blood modifying agent, the body fluid does not remain in the fiber collecting layer 32 covered by the blood modifying agent, moves to the absorbent body 4, and is absorbed in the absorbent body 4, which can be used by using a non-woven fabric covered with a blood modifying agent. The surface sheet is confirmed. With the blood modifying agent, the body fluid does not remain on the surface sheet of the nonwoven fabric, and when the absorbent body is absorbed, the fiber collecting layer 32 is also the same, and the body fluid does not remain in the fiber collecting layer 32, and is absorbed in the absorbent body.

〔example 1〕 [Evaluation of the rate of rewet and the migration speed of the absorber]

Prepare physiological cotton for sale of goods. The sanitary tampon is a surface sheet formed of a hot air non-woven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 35 g/m ² ) treated with a hydrophilic agent, Hot air non-woven fabric (composite fiber made of polyester and polyethylene terephthalate, basis weight: 30g/m ² ), second sheet, wood pulp (basis weight: 150~450g/m ² , center A large number of acrylic acid superabsorbent polymers (basis weight: 15g/m ² ) and an absorbent body containing a toilet paper as a central protrusion, a side sheet treated with a water repellent agent, and a back sheet formed of a polyethylene film Formed by.

The blood modifying agents used in the experiments are listed below.

[(A ₁ ) ester of chain hydrocarbon tetraol with fatty acid]

. Yunisuta H-408BRS, manufactured by Nippon Oil Co., Ltd.

Tetrakilyl tetraethyl 4-ethylhexane

. Yunisuta H-2408BRS-22, manufactured by Nippon Oil Co., Ltd.

Mixture of pentaerythritol tetrakis-2-ethylhexane acid and neopentyl glycol di-2-ethylhexane acid (58:42, weight ratio)

[(A ₂ ) chain hydrocarbon triol and ester of fatty acid]

. Cetiol SB45DEO, manufactured by Cognis Japan Co., Ltd.

Fatty acid is glycerol and fatty acid triester of oleic acid or stearyl acid

. Three C2L oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

C ₈ fatty acid: C ₁₀ fatty acid: C ₁₂ fatty acid contains about glycerol and fatty acid triester in a weight ratio of 37: 7:56

. Tri-CL oil fatty acid glyceride, manufactured by Nippon Oil Co., Ltd.

C ₈ fatty acid and C ₁₂ fatty acid containing glycerol and fatty acid triester in a weight ratio of 44:56

. Panasate 810s, manufactured by Nippon Oil Co., Ltd.

C ₈ fatty acid: C ₁₀ fatty acid contains about glycerol and fatty acid triester in a weight ratio of 85:15

. Panasate800, manufactured by Nippon Oil Co., Ltd.

Fatty acids are octane acid (C ₈ ) glycerol and fatty acid triester

. Panasate800B, manufactured by Nippon Oil Co., Ltd.

Fatty acids are 2-ethyl hexane acid (C ₈ ) glycerol and fatty acid triester

. NA36, made by Nippon Oil Co., Ltd.

C ₁₆ fatty acid: C ₁₈ fatty acid: C ₂₀ fatty acid (containing both saturated and unsaturated fatty acids) contains about glycerol and fatty acid triester in a weight ratio of 5:92:3.

. Three coconut oil fatty acid glyceride, manufactured by Nippon Oil Co., Ltd.

C ₈ fatty acid: C ₁₀ fatty acid: C ₁₂ fatty acid: C ₁₄ fatty acid: C ₁₆ fatty acid (containing both saturated and unsaturated fatty acids) is contained in a weight ratio of 4:8:60:25:3 Glycerol and fatty acid triester

. SOY42, made by Nippon Oil Co., Ltd.

C ₁₄ fatty acids: C ₁₆ fatty acids: C ₁₈ fatty acids: C ₂₀ fatty acids (containing both saturated and unsaturated fatty acids) containing glycerol and fatty acid triesters in a weight ratio of 0.2:11:88:0.8

. Octanoic acid diglyceride, manufactured by Nippon Oil Co., Ltd.

Fatty acid is a diester of glycerol and fatty acid of octanoic acid

[(A ₃ ) ester of chain hydrocarbon diol and fatty acid]

. compoleBL, made by Nippon Oil Co., Ltd.

Dodecanediol (C ₁₂ ) monoester of butanediol

. compoleBS, made by Nippon Oil Co., Ltd.

Butanediol octadecanoic acid (C ₁₈₎ monoesters

. Yunisuta H-208BRS, made by Nippon Oil Co., Ltd.

Diethyl 2-ethylhexane acid neopentyl glycol

[(C ₃₎ having two carboxyl ester chain hydrocarbon dicarboxylic acids, hydroxy acids, alkoxy acid or an aliphatic oxyacid and the monohydric alcohol]

. Dioctyl adipate, manufactured by Wako Pure Chemical Industries

[(D ₃ ) ester of fatty acid with aliphatic monohydric alcohol]

. Erekutol WE20, manufactured by Nippon Oil Co., Ltd.

Ester of dodecanoic acid (C ₁₂ ) and dodecyl alcohol (C ₁₂ )

. Erekutol WE40, manufactured by Nippon Oil Co., Ltd.

Ester of tetradecanoic acid (C ₁₄ ) and dodecyl alcohol (C ₁₂ )

[(E ₁ )Poly C ₂ ~C ₆ alkanediol]

. Youyou Ou Road D-1000 (You You Ou Lu are from Japan Oil Co., Ltd. system)

Polypropylene glycol having a weight average molecular weight of about 1,000

. Youyou Europe Road D-1200

Polypropylene glycol having a weight average molecular weight of about 1,200

. Youyou Europe Road D-3000

Polypropylene glycol having a weight average molecular weight of about 3,000

. Youyou Europe Road D-4000

Polypropylene glycol having a weight average molecular weight of about 4,000

. Youyou Europe Road PB500

Polytetramethylene glycol having a weight average molecular weight of about 500

. Youyou Europe Road PB700

Polyoxybutylene polyoxypropylene glycol having a weight average molecular weight of about 700

. Youyou Europe Road PB1000R

Polytetramethylene glycol having a weight average molecular weight of about 1000

[(E ₂ ) Poly C ₂ ~ C ₆ alkanediol and ester of fatty acid]

. WILBRIDEcp9, made by Nippon Oil Co., Ltd.

The OH groups at both ends are polybutanediol having a weight average molecular weight of about 1,100 by esterification with palmitic acid (C ₁₆ ).

[(E ₃ ) poly C ₂ ~ C ₆ alkanediol and ether of fatty acid]

. You Lupu MS-70K, made by Nippon Oil Co., Ltd.

a stearyl ether of polypropylene glycol, a repeating unit of about 15

[(F ₁ )chain alkane]

. PARLEAM6, manufactured by Nippon Oil Co., Ltd.

Copolymerization of isoparaffin, isobutylene and n-butene, followed by hydrogenation of branched hydrocarbons, degree of polymerization: about 5 to about 10

〔other〕

. NA50, manufactured by Nippon Oil Co., Ltd.

Adding hydrogen to NA36 to reduce the double bond ratio of glycerol and fatty acid from the unsaturated fatty acid of raw materials

. (octanoic acid/capric acid) monoglyceride, manufactured by Nippon Oil Co., Ltd.

Octanoic acid (C ₈ ) and decanoic acid (C ₁₀ ) contain a monoester of glycerol and fatty acid in a weight ratio of 85:15

. Monomuls 90-L2 lauric acid monoglyceride, manufactured by Cognis Japan Co., Ltd.

. Youyou Ux HC60, made by Nippon Oil Co., Ltd.

Polyoxyethylene hardened castor oil

. WILBRIDEs 753, manufactured by Nippon Oil Co., Ltd.

Polyoxyethylene polyoxypropylene polyoxybutylene glycerol

. Isopropyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd.

. Youyou Europe Road D-400

Polypropylene glycol having a weight average molecular weight of about 400

. Youyou Ou Road TG-330, made by Nippon Oil Co., Ltd.

Glycerol ether of polypropylene glycol, repeating unit of about 6, weight average molecular weight: about 330

. You Youou Road TG-1000, made by Nippon Oil Co., Ltd.

Glycerol ether of polypropylene glycol, repeating unit of about 16, weight average molecular weight: about 1000

. You Lupu DGP-700, made by Nippon Oil Co., Ltd.

Diglycerol ether of polypropylene glycol, repeating unit of about 9, weight average molecular weight: about 700

. PEG1500, made by Nippon Oil Co., Ltd.

Polyethylene glycol having a weight average molecular weight of from about 1,500 to about 1,600

. Non-ionic S-6, manufactured by Nippon Oil Co., Ltd.

Polyoxyethylene monostearate, repeat unit of about 7, weight average molecular weight: about 600

. Vaseline, made by CognisJapan Co., Ltd.

Hydrocarbons, semi-solids from petroleum

The IOB, melting point and water solubility of the above samples are shown in Table 2.

Further, the water solubility was measured by the above method, and 20.0 g of 100 g of desalted water was added, and the sample dissolved after 24 hours was evaluated as "20 g <", and 0.05 g of 100 g of demineralized water was dissolved, but 1.00 g was not dissolved. The sample was evaluated to be 0.05 to 1.00 g.

Further, regarding the melting point, "<45" means that the melting point is less than 45 °C.

The skin contact surface of the surface sheet of the above sanitary napkin is coated with the above blood modifying agent. When each blood modifying agent is liquid at room temperature, the following coating is directly performed. If the blood modifying agent is solid at room temperature, it is heated to a melting point of +20 ° C, and secondly, the control slit HMA is used. The gun was micronized with each blood modifying agent and applied to the skin contact surface of the topsheet to a basis weight of about 5 g/m ² .

For Example 1, the range of the surface layer containing the blood modifying agent is shown in FIG. As shown in Fig. 9, in the example 1, the surface layer sheet 220 of the sanitary napkin 200 contains almost all of the blood modifying agent, which is the blood modifying agent containing region 240. And with respect to Figure 9, reference numeral 230 denotes a press section.

〔experiment method〕

On the surface sheet containing each blood modifying agent, place an acrylic plate with a hole (200 mm × 100 mm, 125 g, and a hole of 40 mm × 10 mm in the center). From the above hole, a horse of 37 ± 1 ° C will be placed. EDTA blood (in the blood of horses and in the prevention of coagulation, adding ethyldiaminetetraacetic acid (hereinafter referred to as "EDTA")) 3g, drip using a micropipette (first time), 1 minute later, 37 3 g of horse EDTA blood at ±1 °C, from the hole of the acrylic plate, was again instilled with a micropipette (second time).

Immediately after the second blood drop, the acrylic plate was taken out, and 10 pieces of filter paper (50 mm × 35 mm) were placed in the place where the blood was dropped, and the weight was placed thereon to a pressure of 30 g/cm ² . After 1 minute, the filter paper was taken out, and the "reverse bleed rate" was calculated by the following formula.

Infiltration rate (%) = 100 × (quality of filter paper after test - original filter paper quality) / 6

In addition to the evaluation of the rewet rate, the "absorbent migration speed" of the time when the blood moves from the surface sheet to the absorber after the second blood instillation is measured. The absorption speed of the absorbent body is such that the redness of blood is not visible on the surface and inside of the surface sheet after the absorber is put into the blood. between.

The results of the rate of rewet and the rate of migration of the absorber are shown in Table 2 below.

Moreover, the whiteness of the skin contact surface of the surface sheet after the test of the migration speed of the absorber was visually evaluated based on the following criteria.

◎: The redness of the blood has almost no residue, and it is impossible to distinguish between the place where the blood exists and the place where it does not exist.

○: Although some red blood remains, it is not easy to distinguish between the place where the blood exists and the place where it does not exist.

△: There is a redness of some blood remaining, and the place where the blood exists is known.

×: The redness of the blood directly remains

The combined results are shown in Table 2 below.

When there is no blood modifying agent, the re-infiltration rate is 22.7%, and the migration speed of the absorbent body exceeds 60 seconds, the osmosis rate of glycerol and fatty acid triester is 7.0% or less, and the migration speed of the absorbent body is 8 seconds or less. Therefore, it is known that the absorption performance can be greatly improved. However, in the triester of glycerin and fatty acid, the NA50 having a melting point exceeding 45 ° C did not show a significant improvement in the absorption performance.

Similarly, in a blood modifying agent having an IOB of about 0 to about 0.60, a melting point of about 45 ° C or less, and a water solubility of about 0.05 g or less for 100 g of water at 25 ° C, a large absorption property is known. improve.

Next, after the physiological sanitary napkins of No. 1 to 42 are used by the subjects of the plural volunteers, the physiological sanitary napkins containing the blood modifying agents of No. 1 to 28 are obtained in the surface sheets even after absorption of menstrual blood. There is no sticky feeling, and the surface sheet is also refreshing. In particular, a significant difference was obtained between these and the sanitary napkins of No. 29, 32, 39, 41 and 42.

Further, in the sanitary napkin of No. 1 to 28, in particular, the physiological sanitary napkin containing the blood modifying agent of No. 1 to 11, 15 to 18 and 28 is subjected to skin contact for absorbing surface layer of menstrual blood. The face is not dyed red by the blood, and the answer is less uncomfortable.

[Example 2]

The above-mentioned rewet rate is evaluated for various blood types of animals. The blood used in the experiment is as follows.

[animal species]

(1) Human

(2) Horse

(3) sheep

[blood species]

. Defibration: After blood collection, stir the glass beads in a triangular beaker for about 5 minutes.

. EDTA blood: Add 12% EDTA to venous blood 65mL. 2K physiological saline solution 0.5mL

[segmentation]

Serum or plasma: clear liquid after centrifugation of each defibrinated blood or EDTA blood at room temperature for about 10 minutes at about 1900G

Blood cells: serum is removed from the blood, and the residue is washed twice with phosphate buffered physiological saline solution (PBS), followed by addition of the serum fraction of the phosphate buffered physiological saline solution.

An absorbent article was produced in the same manner as in Example 1 except that the tri-C2L oil fatty acid glyceride was applied to a basis weight of about 5 g/m ² , and the rewet ratio of each of the above blood was evaluated. The measurement of each blood was performed 3 times, and the average value was used.

The results are shown in Table 3 below.

The same tendency as the horse EDTA blood obtained in Example 1 was also obtained in the blood of humans and sheep. Moreover, the same tendency was observed for defibrinated blood and EDTA blood.

[Example 3] [evaluation of blood retention]

The blood retention of the surface layer containing the blood modifying agent and the surface layer containing no blood modifying agent was evaluated.

〔experiment method〕

(1) Three C2L oil fatty acids on the skin contact surface of a surface sheet formed of hot air non-woven fabric (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g/m ² ) The glyceride was micronized using a controlled slit HMA gun and applied to a basis weight of about 5 g/m ² . Further, for comparison, those who have not applied the tri-C2L oil fatty acid glyceride are prepared. Next, both the surface sheet coated with the tri-C2L oil fatty acid glyceride and the uncoated top sheet were cut into a size of 0.2 g, and the mass (a) of the cell filter surface sheet was accurately measured.

(2) About 2 mL of horse EDTA blood was added from the skin contact surface side and left to stand for 1 minute.

(3) The cell filter is placed in a centrifuge tube and stopped to remove excess horse EDTA blood.

(4) The weight (b) of the surface layer containing the cell filter + horse EDTA blood was measured.

(5) The initial absorption amount (g) per 1 g of the surface sheet was calculated according to the following formula.

Initial absorption = [weight (b) - weight (a)] / 0.2

(6) The cell filter was again placed in a centrifuge tube, and centrifuged at about 1200 G for 1 minute at room temperature.

(7) The weight (c) of the surface layer containing the cell filter + horse EDTA blood was measured.

(8) The amount of absorbed (g) per 1 g of the surface sheet was calculated according to the following formula.

Absorption after test = [weight (c) - weight (a)] / 0.2

(9) The blood retention rate (%) was calculated according to the following formula.

Blood retention rate (%) = 100 × absorption after test / initial absorption

Further, the measurement was performed three times, and the average value was used.

The results are shown in Table 4 below.

It means that the surface layer containing the blood modifying agent has low blood retention property and can be quickly moved to the absorber after absorbing blood.

[Example 4] [viscosity of blood containing blood modifying agent]

The blood viscosity of the blood modifying agent was measured using a Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by mass of Panasate 810s was added to the horse's fiber, and the sample was formed by gently stirring, and the sample was placed on a parallel plate having a diameter of 50 mm, and the interval was set to 100 μm, and the viscosity was measured at 37 ± 0.5 °C. On the parallel plate, the sample was not evenly sheared, but the average shear rate displayed by the machine was 10 s ^-1 .

The viscosity of the horse hair fiber containing 2% by mass of Panasate 810s is 5.9 mPa. s, on the other hand, the viscosity of the horse-defibrinated blood without the blood modifying agent is 50.4 mPa. s. Therefore, the horse defibrinated blood containing 2% by mass of Panasate 810s was found to have a viscosity of about 90% lower than that of the case where no blood modifying agent was contained.

The blood contains components such as blood cells and is known to have thixotropic properties. However, the blood modifying agent disclosed in the present invention can lower the viscosity of blood in a low viscosity region. By lowering the viscosity of the blood, the absorbed menstrual blood can be quickly moved from the surface sheet to the absorber.

Since the blood modifying agent can rapidly move the absorbed menstrual blood from the surface layer to the absorber, the blood modifying agent is added to the horse defibrin blood by 2% by mass, and the measurement is performed at 37 ° C and a shearing speed of 10 s ^-1 . At the viscosity, the viscosity of the above-mentioned horse-drawn fiber blood is preferably reduced to at least 50% compared with that before the addition, at least to 60% is preferred, at least to 70% is better, at least to 80% is the most good.

[Example 5] [Micrograph of blood containing blood modifying agent]

On the cling film, the menstrual blood of the volunteers was taken, and in one part, the concentration of Panaseate 810s to Panaseate 810s dispersed in 10 times of the phosphate buffered physiological saline was added in an amount of 1% by mass. The menstrual blood was dripped on a glass slide, covered with a cover glass, and the state of the red blood cells was observed with an optical microscope. A microscope photograph of menstrual blood containing no blood modifying agent is shown in Fig. 10 (a), and a microscope photograph of menstrual blood containing Panasate 810s is shown in Fig. 10 (b).

As shown in Fig. 10, in the menstrual blood containing no blood modifying agent, red blood cells form aggregates such as money strings, but in menstrual blood containing Panasate 810s, red blood cells are stably dispersed. Therefore, the blood modifying agent exhibits the function of stabilizing red blood cells in the blood.

[Example 6] [surface tension of blood containing blood modifying agent]

The surface tension of the blood containing the blood modifying agent was measured by a pendant method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. The surface tension is a blood modifying agent added to the defibrinated blood of the sheep, and is measured after being sufficiently vibrated.

The measurement was performed automatically by a machine, and the density γ was obtained by the following formula (refer to FIG. 11).

γ=g×ρ×(de) ² ×1/H

g: gravity constant

1/H: Correction obtained by ds/de

ρ: density

De: maximum diameter

Ds: diameter by which the drop end is only raised

The density ρ is measured at the temperature shown in Table 5 in accordance with the 5. Vibration Density Test Method of "Density Test Method and Density, Mass, Capacity Conversion Table" of JIS K 2249-1995.

The measurement was performed using DA-505 of Kyoto Electronics Industry Co., Ltd.

The results are shown in Table 5 below.

As is clear from Table 5, the blood modifying agent has a water solubility of 0.05 g or less for 100 g of water at 25 ° C, and the solubility in water is extremely low, and the surface tension of blood can be lowered.

By lowering the surface tension of the blood, the absorbed blood is not held between the fibers of the surface sheet, and can be quickly moved to the absorber.

1‧‧‧Absorbables

2‧‧‧Skin sheet

3‧‧‧Back sheet

4‧‧‧Acceptor

5‧‧‧ wings

6‧‧‧Adhesive

21‧‧‧Bulge

22‧‧‧ bottom

23‧‧‧ top

24‧‧‧ wall

31‧‧‧ resin film layer

32‧‧‧Fiber collection layer

33‧‧‧Modifier layer

34‧‧‧ openings

100‧‧‧Surface sheet manufacturing equipment

103,104‧‧‧Composite sheets

130‧‧‧Extended tooth roll

131‧‧‧Upper tooth roll

132‧‧‧lower tooth roller

133,134‧‧‧ gear teeth

140‧‧‧ Blood Modifier Coating Spray

141‧‧‧ Blood Modifier

200‧‧‧Physical sanitary napkins

210‧‧‧Skin sheet

230‧‧‧Squeeze

240‧‧‧ Blood Modifier Containing Area

BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a partially broken plan view showing an embodiment of an absorbent article of the present invention.

2 and 2 are schematic cross-sectional views of the A-A broken plane shown in Fig. 1.

Fig. 3 Fig. 3 is a detailed explanatory view of a surface sheet according to an embodiment of the present invention.

4 to 4 are explanatory views of a method of manufacturing a surface sheet according to an embodiment of the present invention.

5(a) and 5(b) are explanatory views of an extension tooth roll used in a method of manufacturing a surface sheet according to an embodiment of the present invention.

Figure 6 Figure 6 is a description of the resin film extended by the extending tooth roll Figure.

Fig. 7 Fig. 7 (a), Fig. 7 (b), and Fig. 7 (c) are microscopic photographs of the skin side of the surface layer sheet in which the opening portion is formed in the resin film layer.

Fig. 8 Fig. 8(a) and Fig. 8(b) are micrographs of the garment side of the surface sheet in which the opening of the resin film layer is formed.

Fig. 9 and Fig. 9 are diagrams showing the range of the surface layer containing the blood modifying agent in Example 1.

Fig. 10 Fig. 10(a) and Fig. 10(b) are micrographs of menstrual blood with or without a blood modifying agent.

Fig. 11 and Fig. 11 are explanatory views of a method of measuring surface tension.

1‧‧‧Absorbables

2‧‧‧Skin sheet

3‧‧‧Back sheet

4‧‧‧Acceptor

5‧‧‧ wings

7‧‧‧ Sealing Department

Claims (31)

An absorbent article comprising a liquid-permeable surface sheet provided on the skin side, a liquid-impermeable back sheet provided on the garment side, and a surface sheet disposed between the surface sheet and the back sheet The liquid-retaining absorbent body is characterized in that the surface layer sheet contains a resin film layer, a fiber assembly layer provided on the garment side of the resin film layer, and a blood modifying agent provided on the skin side of the resin film layer. In the layer, the surface layer sheet has a plurality of ridge portions arranged in parallel and a bottom portion disposed between the adjacent ridge portions, and the ridge portion includes the resin film layer on the side surface of the ridge portion. a wall portion having a plurality of parallel openings in the extending direction, wherein the fibers of the fiber assembly layer are covered with a blood modifying agent of the blood modifying agent layer, and the blood modifying agent has an IOB of 0 to 0.60 and a temperature of 45° C. or less. Melting point, water solubility of 0.05 g or less per 100 g of water at 25 °C. The absorbent article of claim 1, wherein the fiber collection layer is a person applying the blood modifying agent. The absorbent article of claim 1 or 2, wherein the blood modifying agent is (i) a hydrocarbon, (ii) a CC single bond between hydrocarbons, and at least one carbonyl bond (-CO-) is inserted. And/or at least one compound of an ether bond (-O-), or (iii) at least one carbonyl bond (-CO-) and/or at least one ether bond (-O) between CC single bonds of a hydrocarbon. -), and at least one hydrogenogen on the hydrocarbon A compound substituted with a carboxyl group (-COOH) or a hydroxyl group (-OH); wherein, for the compound of (ii) or (iii), when two or more ether bonds are inserted, the ether bonds are not adjacent to each other. The absorbent article of claim 1 or 2, wherein the blood modifying agent is (i') hydrocarbon, (ii') is inserted between CC single bonds of hydrocarbons, and at least one carbonyl bond is inserted (-CO) -), at least one ester bond (-COO-), at least one carbonate bond (-OCOO-) and/or at least one ether bond (-O-) compound, or (iii') hydrocarbon CC Between the single bonds, at least one carbonyl bond (-CO-), at least one ester bond (-COO-), at least one carbonate bond (-OCOO-), and/or at least one ether bond (-O-) are inserted. And a compound in which at least one hydrogen atom on the hydrocarbon is substituted by a carboxyl group (-COOH) or a hydroxyl group (-OH); wherein, for a compound of (ii') or (iii'), when two or more bonds are inserted , each bond will not be adjacent. The absorbent article according to claim 1 or 2, wherein the blood modifying agent has a carbonyl bond (-CO-) of 1.8 or less per 10 carbon atoms in the hydrocarbon, and the ester bond (-COO-) 2 or less, a compound having a carbonate bond (-OCOO-) of 1.5 or less, an ether bond (-O-) of 6 or less, a carboxyl group (-COOH) of 0.8 or less, and/or a hydroxyl group (-OH) of 1.2 or less. The absorbent article according to claim 1 or 2, wherein the blood modifying agent is (A) an ester having a compound having 2 to 4 hydroxyl groups and a compound having one carboxyl group, and (B) having 2~ An ether of a compound having 4 hydroxyl groups and a compound having 1 hydroxyl group, (C) an ester of a compound having 2 to 4 carboxyl groups and a compound having 1 hydroxyl group, and (D) a hydrocarbon insertion selected from an ether bond (-O- a compound of any one of the group consisting of a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonate bond (-OCOO-), (E) a poly C ₂ -C ₆ alkanediol, Or its ester or ether or (F) chain hydrocarbon. The absorbent article according to claim 1 or 2, wherein the blood modifying agent is an ester selected from the group consisting of (A ₁ ) chain hydrocarbon tetraol and fatty acid, (A ₂ ) chain hydrocarbon triol and fatty acid Ester, (A ₃ ) chain hydrocarbon diol and fatty acid ester, (B ₁ ) chain hydrocarbon tetraol and aliphatic monohydric alcohol ether, (B ₂ ) chain hydrocarbon triol and aliphatic monohydric alcohol Ether, (B ₃ ) chain hydrocarbon diol and aliphatic monohydric alcohol ether, (C ₁ ) chain hydrocarbon tetracarboxylic acid having 4 carboxyl groups, hydroxy acid, alkoxy acid or oxo acid An ester with an aliphatic monohydric alcohol, (C ₂ ) a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or an ester of an oxo acid and an aliphatic monohydric alcohol, (C ₃ ) a chain of two carboxyl-chain hydrocarbon dicarboxylic acids, a hydroxy acid, an alkoxy acid or an oxo acid and an aliphatic monohydric alcohol, (D ₁ ) an aliphatic monohydric alcohol and an aliphatic monohydric alcohol ether, (D ₂ ) dialkyl ketone, ester of (D ₃ ) fatty acid with aliphatic monohydric alcohol, (D ₄ ) dialkyl carbonate, (E ₁ ) poly C ₂ ~ C ₆ alkanediol, (E ₂ ) poly C ₂ ~ C ₆ alkanediol and fatty acid ester, (E ₃ ) poly C ₂ ~ C ₆ alkanediol and aliphatic 1 alcohol ether, (E ₄ ) poly C ₂ ~ C ₆ alkanediol and chain Hydrocarbon four a carboxylic acid, a chain hydrocarbon tricarboxylic acid or an ester of a chain hydrocarbon dicarboxylic acid, (E ₅ ) a poly C ₂ -C ₆ alkanediol and a chain hydrocarbon tetraol, a chain hydrocarbon triol, or a chain hydrocarbon The alcohol ether and the (F ₁ ) chain alkane are grouped. The absorbent article according to claim 1 or 2, wherein the blood modifying agent has a weight average molecular weight of 2,000 or less. An absorbent article according to claim 1 or 2, wherein the fiber collection layer contains toilet paper. The absorbent article according to claim 1 or 2, wherein the opening area of the opening is 0.0005 mm ² or more and 1.5 mm ² or less. The absorbent article according to claim 1 or 2, wherein the resin film layer has an opening ratio of 1% or more and 10% or less. A surface sheet which is a liquid-permeable surface sheet for use in an absorbent article, characterized in that the surface layer sheet comprises a resin film layer, a fiber assembly layer provided on one surface of the resin film layer, and the other resin film layer a blood modifying agent layer provided on the surface, wherein the surface layer sheet has a plurality of ridge portions arranged in parallel and a bottom portion disposed between the ridge portions, and the ridge portion includes the resin film layer on a side surface thereof a wall portion having a plurality of parallel openings in a direction in which the protruding portion extends; the fibers of the fiber assembly layer are covered by a blood modifying agent of a blood modifying agent layer, and the blood modifying agent has a value of 0 to 0.60. IOB, a melting point of 45 ° C or less, and a surface layer of water solubility of 0.05 g or less of 100 g of water at 25 ° C. Such as the surface layer of claim 12, wherein the fiber The dimension collecting layer is coated with the aforementioned blood modifying agent. The surface layer of claim 12 or 13, wherein the blood modifying agent is (i) a hydrocarbon, (ii) a CC single bond between hydrocarbons, and at least one carbonyl bond (-CO-) is inserted / or at least one compound of an ether bond (-O-), or (iii) between at least one CC bond of a hydrocarbon, at least one carbonyl bond (-CO-) and/or at least one ether bond (-O-) And a compound in which at least one hydrogen atom on the hydrocarbon is substituted by a carboxyl group (-COOH) or a hydroxyl group (-OH); wherein, for the compound of (ii) or (iii), when two or more ether bonds are inserted, an ether bond They will not be adjacent to each other. The surface layer of claim 12 or 13, wherein the blood modifying agent is (i') hydrocarbon, (ii') is between the CC single bonds of the hydrocarbon, and at least one carbonyl bond is inserted (-CO- a compound having at least one ester bond (-COO-), at least one carbonate bond (-OCOO-), and/or at least one ether bond (-O-), or (iii') a hydrocarbon CC Between the bonds, at least one carbonyl bond (-CO-), at least one ester bond (-COO-), at least one carbonate bond (-OCOO-), and/or at least one ether bond (-O-) are inserted. And a compound in which at least one hydrogen atom on the hydrocarbon is substituted by a carboxyl group (-COOH) or a hydroxyl group (-OH); wherein, when two or more bonds are inserted in the compound of (ii') or (iii'), The bonds do not abut. For example, if the surface layer of the 12th or 13th article of the patent application is applied, The blood modifying agent has 1.8 or less carbonyl bonds (-CO-), 2 or less ester bonds (-COO-), and 1.5 or less carbonate bonds (-OCOO-) per 10 carbon atoms in the hydrocarbon. A compound having 6 or less ether bonds (-O-), 0.8 or less carboxyl groups (-COOH), and/or 1.2 or less hydroxyl groups (-OH). The surface layer of claim 12 or 13, wherein the blood modifying agent is (A) an ester having a compound having 2 to 4 hydroxyl groups and a compound having 1 carboxyl group, and (B) having 2 to 4 An ester of a hydroxyl group compound with a compound having one hydroxyl group, (C) an ester of a compound having 2 to 4 carboxyl groups and a compound having 1 hydroxyl group, and (D) a hydrocarbon insertion selected from an ether bond (-O-) a compound of any one of a group consisting of a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonate bond (-OCOO-), (E) a poly C ₂ -C ₆ alkanediol, or Its ester or ether or (F) chain hydrocarbon. The surface layer of claim 12 or 13, wherein the blood modifying agent is selected from the group consisting of (A ₁ ) chain hydrocarbon tetraol and fatty acid ester, (A ₂ ) chain hydrocarbon triol and fatty acid. Esters, esters of (A ₃ ) chain hydrocarbon diols and fatty acids, (B ₁ ) chain hydrocarbon tetraols and aliphatic monohydric alcohol ethers, (B ₂ ) chain hydrocarbon triols and aliphatic monohydric alcohols Ether, (B ₃ ) chain hydrocarbon diol and aliphatic monohydric alcohol ether, (C ₁ ) chain hydrocarbon tetracarboxylic acid having 4 carboxyl groups, hydroxy acid, alkoxy acid or oxyacid and aliphatic 1 An ester of a diol, (C ₂ ) a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or an ester of an oxyacid with an aliphatic monohydric alcohol, and (C ₃ ) a chain having two carboxyl groups a hydrocarbon dicarboxylic acid, a hydroxy acid, an alkoxy acid or an ester of an oxo acid with an aliphatic monohydric alcohol, (D ₁ ) an aliphatic monohydric alcohol and an aliphatic monohydric alcohol ether, (D ₂ ) dialkyl ketone , (D ₃ ) ester of fatty acid with aliphatic monohydric alcohol, (D ₄ ) dialkyl carbonate, (E ₁ ) poly C ₂ ~ C ₆ alkanediol, (E ₂ ) poly C ₂ ~ C ₆ alkane and fatty acid esters of glycols, ethers (E ₃₎ poly C ₂ ~ C ₆ alkylene glycol and the aliphatic monohydric alcohol, (E ₄₎ poly C ₂ ~ C ₆ alkylene glycol and a chain hydrocarbon tetracarboxylic acid, Esters of a hydrocarbon-like chain hydrocarbon tricarboxylic acid or of a dicarboxylic acid, (E ₅₎ poly C ₂ ~ C ₆ alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol of the ether, And (F ₁ ) a chain of alkanes. The surface layer sheet of claim 12 or 13, wherein the blood modifying agent has a weight average molecular weight of 2,000. A surface sheet according to claim 12 or 13, wherein the fiber collection layer contains toilet paper. The surface layer sheet of claim 12 or 13, wherein the opening area of the opening portion is 0.0005 mm ² or more and 1.5 mm ² or less. The surface layer sheet of the 12th or 13th aspect of the invention, wherein the resin film layer has an aperture ratio of 1% or more and 10% or less. A method for producing a surface sheet for use in an absorbent article, comprising the steps of: preparing a composite sheet containing a fiber assembly layer and a resin film layer; and stretching the composite sheet to form a plurality of sheets in parallel with each other; a step of forming a ridge a step of applying a blood modifying agent to the surface of the resin film layer of the composite sheet; the ridge portion formed by the step of forming the ridge portion of the composite sheet is provided with the resin film layer and having the ridge portion The fiber of the fiber assembly layer is covered with the blood modifying agent in the wall portion of the plurality of openings in the extending direction, and the blood modifying agent has an IOB of 0 to 0.60 and a melting point of 45° C. or less, and a melting point of 25° C. Water solubility of 0.05 g or less of 100 g of water. The method for producing a surface layer sheet according to claim 23, further comprising the step of applying a blood modifying agent to the surface of the fiber assembly layer of the composite sheet forming the ridge portion. The method for producing a surface sheet according to claim 23 or claim 24, wherein the blood modifying agent is (i) a hydrocarbon, (ii) a CC single bond between hydrocarbons, and at least one carbonyl bond is inserted (-CO) -) and / or at least one compound of an ether bond (-O-), or (iii) intercalating at least one carbonyl bond (-CO-) and/or at least one ether bond between CC single bonds of a hydrocarbon ( -O-), and a compound in which at least one hydrogen atom on a hydrocarbon is substituted by a carboxyl group (-COOH) or a hydroxyl group (-OH); wherein, for a compound of (ii) or (iii), when two or more ether linkages are inserted The ether bonds do not abut each other. The method for producing a surface sheet according to claim 23 or claim 24, wherein the blood modifying agent is (i') hydrocarbon, (ii') is inserted between CC single bonds of hydrocarbons, and at least one carbonyl bond is inserted ( -CO- a compound having at least one ester bond (-COO-), at least one carbonate bond (-OCOO-), and/or at least one ether bond (-O-), or (iii') a hydrocarbon CC Between the bonds, at least one carbonyl bond (-CO-), at least one ester bond (-COO-), at least one carbonate bond (-OCOO-), and/or at least one ether bond (-O-) are inserted. And a compound in which at least one hydrogen atom on the hydrocarbon is substituted by a carboxyl group (-COOH) or a hydroxyl group (-OH); wherein, when two or more bonds are inserted in the compound of (ii') or (iii'), The bonds do not abut. The method for producing a surface sheet according to claim 23 or claim 24, wherein the blood modifying agent has a carbonyl bond (-CO-) of 1.8 or less per 10 carbon atoms in the hydrocarbon, and an ester bond (- 2 or less COO-), 1.5 or less carbonate bonds (-OCOO-), 6 or less ether bonds (-O-), 0.8 or less carboxyl groups (-COOH), and/or 1.2 or less hydroxyl groups (-OH). Compound. The method for producing a surface sheet according to claim 23 or claim 24, wherein the blood modifying agent is (A) an ester having a compound having 2 to 4 hydroxyl groups and a compound having one carboxyl group, and (B) having An ester of a compound having 2 to 4 hydroxyl groups and a compound having 1 hydroxyl group, (C) an ester of a compound having 2 to 4 carboxyl groups and a compound having 1 hydroxyl group, and (D) a hydrocarbon insertion selected from an ether bond (- O-), a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonate bond (-OCOO-) in a group of any one of the compounds, (E) poly C ₂ ~ C ₆ alkane An alcohol, or an ester or ether thereof or (F) a chain hydrocarbon. The method for producing a surface sheet according to claim 23 or claim 24, wherein the blood modifying agent is an ester selected from the group consisting of (A ₁ ) chain hydrocarbon tetraol and a fatty acid, (A ₂ ) chain hydrocarbon triol Ester with fatty acid, (A ₃ ) chain hydrocarbon diol and fatty acid ester, (B ₁ ) chain hydrocarbon tetraol and aliphatic monohydric alcohol ether, (B ₂ ) chain hydrocarbon triol and aliphatic 1 a ether of a diol, a (B ₃ ) chain hydrocarbon diol and an ether of an aliphatic monohydric alcohol, (C ₁ ) a chain hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxy acid, an alkoxy acid or an oxo acid An ester of an aliphatic monohydric alcohol, (C ₂ ) a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or an ester of an oxo acid and an aliphatic monohydric alcohol, and (C ₃ ) having two a chain hydrocarbon dicarboxylic acid of a carboxyl group, a hydroxy acid, an alkoxy acid or an ester of an oxo acid and an aliphatic monohydric alcohol, (D ₁ ) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, (D ₂ ) Dialkyl ketone, (D ₃ ) fatty acid and aliphatic monohydric alcohol ester, (D ₄ ) dialkyl carbonate, (E ₁ ) poly C ₂ ~ C ₆ alkanediol, (E ₂ ) poly C ₂ ~ Ester of C ₆ alkanediol and fatty acid, (E ₃ ) poly C ₂ ~C ₆ alkanediol and ether of aliphatic monohydric alcohol, (E ₄ ) poly C ₂ ~C ₆ alkanediol and chain hydrocarbon Tetracarboxylic acid, chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid ester, (E ₅ ) poly C ₂ ~ C ₆ alkanediol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon The ether of the diol and the (F ₁ ) chain alkane are grouped. The method for producing a surface sheet according to claim 23 or claim 24, wherein the blood modifying agent has a weight average molecular weight of 2,000 or less. A method of producing a surface sheet according to claim 23 or claim 24, wherein the fiber sheet is a toilet paper sheet.